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ABSTRACT

Inappropriate expression of embryonic genes, particularly homeodomain
transcription factors, contributes to tumorigenesis and tumor progression. The
overexpression of Six1, a member of the Six family of homeodomain transcription
factors, has been found in various human cancers, and is associated with tumor
progression and metastasis. We have previously determined that the expression of SIX1
mRNA increased during in vitro progression of human papillomavirus type 16 (HPV16)immortalized human keratinocytes (HKc/HPV16) toward a differentiation-resistant
(HKc/DR) phenotype. However, the mechanism(s) of how Six1 promotes HPV16mediated transformation remain unknown. In this study, we explored the role of Six1 at
early stages and late stages of HPV16-mediated transformation by overexpressing Six1 in
HKc/HPV16 and HKc/DR. We found that HKc/HPV16 and HKc/DR overexpressing
Six1 exhibited a more mesenchymal phenotype compared to vector controls, as
characterized by a fibroblastic appearance and increased invasion. We utilized Whole
Human Genome Microarrays to explore the gene expression changes associated with
Six1 overexpression in HKc/HPV16 and HKc/DR. Using a combination of KEGG
pathway analysis, realtime PCR, and Western blotting, we determined that
overexpression of Six1 downregulated epithelial-related genes and upregulated
mesenchymal-related genes, which suggests that Six1 overexpression induces epithelialmesenchymal transition (EMT). In addition, we observed alterations in the transforming
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growth factor-beta (TGF-β) pathway and activation of the Mitogen-activated protein
kinase (MAPK) pathway in response to Six1 overexpression, indicating that Smadindependent pathways of TGF-β signaling may be involved in Six1-mediated EMT.
Moreover, the overexpression of Six1 in HKc/HPV16 resulted in resistance to serum and
calcium-induced differentiation, which is the hallmark of the HKc/DR phenotype; while
Six1 overexpression in HKc/DR resulted in malignant conversion and increased the
cancer stem cell (CSC)-like population. The activation of MAPK is linked to Six1mediated resistance to calcium-induced differentiation in HKc/HPV16 and Six1associated features of CSCs in HKc/DR. Finally, we used a series of MAPK inhibitors to
further demonstrate the important role MAPK activation plays in Six1-induced EMT and
CSCs properties. Taken together, this study determined that Six1 overexpression resulted
in differentiation resistance and promoted EMT at early stages of HPV16-mediated
transformation, and Six1 overexpression promotes EMT, CSCs properties, and malignant
conversion at late stages of HPV16-mediated transformation of HKc.
We also used an orthotopic mouse model and a splenic injection metastasis model
to investigate the role of Six1 overexpression in colorectal cancer (CRC) progression and
metastasis. We found that overexpression of Six1 dramatically promoted CRC tumor
growth and metastasis in vivo, increased features of cancer stem cells (CSCs), and
stimulated angiogenesis by up-regulating the expression of vascular endothelial growth
factor (VEGF). Moreover, we determined that Six1 overexpression results in the
recruitment of tumor-associated macrophages (TAM) by increasing the expression of
macrophage-specific colony-stimulating factor-1 (CSF-1), chemokine (C-C motif) ligand
2/5 (CCL2/5) and VEGF, which further facilitates CRC tumor growth and metastasis.
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Furthermore, we determined that Six1 activated ERK and p38 MAPK signaling in MC38
CRC cells. In summary, our studies strongly suggest that Six1 overexpression promotes
malignant progression in models of cervical and colon cancer, and MAPK activation may
play a pivotal role in Six1-associated tumor progression.
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CHAPTER 1
INTRODUCTION

1.1 SIX1 AND ITS ROLE IN TUMORIGENESIS
Six1 (sine oculis homeobox 1) is a member of the Six family of homeodomain
transcription factors. The Six family members are homologous to Drosophila sine oculis
(So), Optix and Dsix4 genes. Six family genes have been identified in many species,
including human, mouse, chicken, frog and fish, but no homologues have been found in
unicellular organisms such as yeast. Six1 family proteins are characterized by the
presence of two conserved domains: Six-type homeodomain (HD, 60 amino acids) and
Six1-domain (SD, 110-115 amino acids). Based on the amino acid sequence similarities
of HDs and SDs, the Six family can be classified into three subfamilies: Six1/Six2 (So),
Six3/Six6 (Optix), and Six4/Six5 (Dsix4) in vertebrates (Figure 1.1). HDs generally
contain a helix-turn-helix (HTH) motif and mediate DNA binding. The consensus
binding site for mammalian Six1/2/4/5 is TCAGGTTC, which is similar to the sequence
that is bound by Drosophila So. The binding sites for Six family proteins in flies and
worms are TGATAC and GGGTATCA. In contrast, the binding site for Six3/6 contains
the conserved homeobox binding core sequence ATTA, thus it is significantly different
from the DNA sequences bound by other subfamilies. The SDs are critical for mediating
protein-protein interactions. The first identified interaction between a Six protein and a
transcriptional co-activator is the physical interaction between Drosophila So and Eyes
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Absent (Eya). Loss-of-function mutations in either gene cause the complete loss of the
retina. In addition, Six proteins can interact with Gro or DACH to suppress/silence
downstream targets (Kawakami et al., 2000; Kumar, 2009; Larder et al., 2011).

Figure 1.1 Schematic representations of the mouse Six proteins showing their
characteristic structural features: the Six domain (SD, blue) and the Six-type
homeodomain (HD, yellow). The numbers indicate the percentage of amino acid
identity between the SDs and between the HDs. The transcription activation
domains (AD) of Six4 and Six5 have been marked as gray shading in the Cterminal.
The human Six1 gene is located on chromosome 14q23.1 and in composed of 2
exons and one intron. The transcript length is 1,376 base pairs, which codes for a protein
of 284 amino acids with a mass of 32,210 Daltons (Figure 1.2) (GenBank accession no
NM_005982, (Sanggaard et al., 2007). Six1 is broadly expressed in various tissues and
organs, and plays a critical role in tissue and organ development, including muscle
(Laclef et al., 2003a), the auditory system (Zheng et al., 2003), olfaction (Ikeda et al.,
2010), and kidney (Xu et al., 2003). Six1-/- mice die at birth and show multiple organ
developmental defects, including rib defects, muscle hypoplasia, absence of kidneys and
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thymus, craniofacial defects, and ear and nose defects (Laclef et al., 2003b). Six1 +/mice show partial hearing loss because of a failure of sound transmission in the middle
ear (Zheng et al., 2003). Six1 activates the expression of target genes by binding to MEF3,
SRE1 and other putative DNA–binding sequences (Liu et al., 2012). For instance, Six1
regulates the expression of Myogenin by binding to a conserved MEF3 site in the
promoter, which regulates myogenesis (Spitz et al., 1998). Six1 utilizes co-factors,
coactivators and corepressors, to regulate the transcription of target genes. For example,
the formation of an Eya1-Six1 complex is essential for auditory system development (Ruf
et al., 2004), and the phosphatase activity of Eya3 switches the function of Six1-Dach
from repression to transcriptional activation through recruitment of the co-activator CBP
(Li et al., 2003).

Figure 1.2 Human Six1 gene and protein. Upper panel: the human
Six1 gene is composed of 2 exons that are 833 and 543 base pairs
(bp) respectively, and a 2052-bp intron. The start and stop codons
are shown. Lower panel: the human Six1 protein (total length of 284
amino acids) that contains an N-terminal SD (115 amino acids) and
a C-terminal HD (60 amino acids) domain.
Many studies have shown that inappropriate expression of embryonic genes,
particularly homeodomain transcription factors, contributes to tumorigenesis and/ or
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tumor progression (Abate-Shen, 2002). Six1 overexpression has been found in various
adult human cancers including breast (Coletta et al., 2008), ovarian (Behbakht et al.,
2007), cervical (Wan et al., 2008; Zheng et al., 2010), colorectal (Ono et al., 2012) and
hepatocellular carcinomas (HCC) (Ng et al., 2010), as well as pediatric malignancies
such as rhabdomyosarcomas (Yu et al., 2004) and Wilms’ tumors (Li et al., 2002). The
overexpression of Six1 is associated with increased tumor progression and decreased
survival (Christensen et al., 2008). For example, Six1 is overexpressed in 50% of primary
mammary carcinomas and 90% of metastatic lesions (Reichenberger et al., 2005). The
expression of SIX1 mRNA was detected in about 85% of hepatocellular carcinomas
(HCC), while expression was observed in only 8.3% of HCC non-tumor adjacent liver
tissue and 10% of normal liver tissue. Consistently, Six1 protein was detected in about 60%
of tumor tissue while no Six1 protein was found in adjacent non-tumor liver tissues and
normal liver. The elevated Six1 expression in HCC patients is related to advanced stage
and poor overall survival (Ng et al., 2006). Six1 is also overexpressed in cervical cancer
cell lines and cervical cancer tissues, and the extent of Six1 overexpression is correlated
to increased malignancy and lymph node metastasis (Tan, Zhang, and Qian, 2011; Wan
et al., 2008; Zheng et al., 2010).
Among these cancers, the functions of Six1 in breast cancer are the most
extensively investigated. The major roles Six1 plays in breast cancer include: (1) Six1
overexpression increases cell proliferation in breast cancer by directly up-regulating
cyclin A1 transcription (Coletta et al., 2004); (2) The overexpression of Six1 in
immortalized and nontumorigenic mammary epithelial cells induces genomic instability
and malignant transformation, leading to highly aggressive and invasive tumors in nude
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mice (Coletta et al., 2008); (3) Six1-overexpresstion in human breast cancer cell lines
promotes epithelial-mesenchymal transition (EMT) and enhances metastasis in vitro and
in vivo [27,28]; (4) EMT resulting from Six1 overexpression is associated with Smaddependent transforming growth factor-beta (TGF-β) signaling and increased expression
of TGF-β receptor type I (TβRI) (Micalizzi et al., 2009; Micalizzi et al., 2010); and (5)
Six1 induces lymphangiogenesis and distant metastasis in breast cancer by up-regulating
VEGF-C, a specific lymphangiogenic factor (Wang et al., 2012). Besides cyclin A1,
other pro-tumorigenic genes can be regulated by Six1, such as cyclin D1, c-Myc, and
Ezrin (Yu et al., 2006). For instance, Six1 promotes cell cycle progression and
proliferation in pancreatic cancer cells by upregulating cyclin D1 expression (Li et al.,
2013). Ezrin is responsible for Six1-induced metastasis in a series of representative
pediatric cancers (Yu et al., 2006).

1.2 EPITHELIAL-MESENCHYMAL TRANSITION (EMT)
EMT is a dynamic process that allows immotile and highly polarized epithelial
cells acquire a motile, apolar and fibroblastic phenotype (Figure 1.3). In normal
physiology, EMT is required for proper tissue organization, normal embryonic
development, wound healing, and in the repair of damaged tissue.

EMT is also

considered a critical step in mediating the acquisition of metastasis. EMT allows tumor
cells to migrate from the primary tumor into surrounding tissue, intravasate into the
vasculature and lymphatics, and extravasate at a secondary site, leading to tumor cell
dissemination and colonization of distant organs (Figure 1.4) (Christiansen and
Rajasekaran, 2006).
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Figure 1.3 The morphologic and genetic changes during epithelialmesenchymal transition (EMT).
EMT is defined by the morphologic and genetic transition of epithelial cells to
mesenchymal-like cells (Figure 1.3). In response to the initiation of EMT, cell-cell
junctions disassemble and filamentous actin is redistributed to stress fibers. Molecular
alterations underlying EMT including the decreased expression of cell-cell junction
proteins such as E-cadherin, claudins and occludins, and increased expression of
mesenchymal markers such as N-cadherin, fibronectin, vimentin and α-smooth muscle
actin (α-SMA). In addition, numerous transcription factors are upregulated by EMT
inducers in variety of cancers, such as snail1, snail2, twist, ZEB1 and ZEB2 (Wendt,
Allington, and Schiemann, 2009).
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Figure 1.4 EMT facilitates tumor metastasis. Primary tumor cells undergo
EMT to invade into surrounding tissue, intravasate into the vasculature and
lymphatics, extravasate at a secondary site, leading to metastasis. At the
distant site the cells can undergo mesenchymal-epithelial transition (MET).
The induction of EMT in response of Six1 overexpression has been observed in
various cancers. Six1 induces human mammary carcinoma cells to undergo EMT by
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enhancing TGF-β signaling (Micalizzi et al., 2009). In colorectal cancer, Six1 promotes
EMT through posttranscriptional ZEB1 activation and transcriptional repression of the
miR-200-family (Ono et al., 2012). A recent study indicates a possible role of Six family
members in regulating developmental EMT and maintaining mesenchymal progenitor
renewal (Grifone et al., 2005; Self et al., 2006). In all, Six family proteins are critical
regulators of EMT in both development and tumor progression.

1.3 THE ROLES OF TRANSFORMING GROWTH FACTOR-BETA (TGF-β)
SIGNALING IN CANCER.
TGF-β is a multifunctional cytokine that is involved in many aspects of cell
development, differentiation and homeostasis. TGF-β contains three isoforms: TGFβ1,
TGFβ2, and TGFβ3. TGF-β dimers mediate signaling by binding to three high-affinity
receptors, called TGF-β receptor type I (TβRI), type II (TβRII) and type III (TβRIII).
TβRIII is the most abundant TGF-β receptor and its function is to assist TGF-β binding to
TβRII. TβRI and TβRII both have intrinsic Ser/Thr protein kinase activity in their
cytoplasmic domains. In Smad-dependent (canonical) TGF-β signaling, the binding of
TGF-β to TβRII recruits and then phosphorylates TβRI, leading to the phosphorylation of
Smad2/3 proteins and induction of canonical Smad2/3-dependent signaling. Once
activated, Smad2/3 form heterocomplexes with Smad4 and shuttle into the nucleus,
where the complex regulates the transcription of a large number of target genes (Figure
1.5).
Each step in TGF-β signaling is highly regulated. First of all, the phosphorylation
of Smads is reversed by phosphatases, which forming a rapid activation-deactivation
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cycle. Secondly, activated Smad2/3 can be targeted by ubiquitin E3 ligases for
degradation. Thirdly, the interaction between Smad2 and Smad4 is disrupted by monoubiquitination of Smad4. In addition, the inhibitory Smads (I-Smads) are transcriptionally
induced upon activation of TGF-β signaling (Derynck and Zhang, 2003; Meulmeester
and Ten Dijke, 2011).

Figure 1.5 Smad-dependent (canonical) TGF-β signaling.
Besides Smad-dependent signaling, there are a variety of Smad-independent
(noncanonical) signaling pathways, including the mitogen-activated protein kinase
(MAPK) pathway, the phosphatidylinositol-3-kinase (PI3K)/AKT pathway and Rho-like
GTPase signaling pathway (Figure 1.6). Below is a description of each of these nonSmad signaling pathways.
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The ERK non-Smad pathway: TGF-β induces phosphorylation of TβRI/II and
Shc (Src homology domain 2 containing) (Lee et al., 2007), which enables the
recruitment of the Grb2/SOS complex and the sequential activation of Ras, Raf, and the
ERK MAPK cascade (Hartsough and Mulder, 1995).

ERK regulates target gene

transcription through its downstream transcription factors (such as AP-1 family members)
in conjunction with Smads to promote EMT, which mediates tumor invasiveness and
metastasis (Davies et al., 2005; Zhang, Feng, and Derynck, 1998). ERK can also
phosphorylate and inhibit the activity of the receptor-activated Smads (Smads 2/3), which
may explain how oncogenic Ras overrides TGF-β-mediated growth arrest in cancer cells
(Kretzschmar et al., 1999).
The JNK/p38 non-Smad pathway:

JNK/p38 MAPK signaling is the best-

characterized non-Smad pathway. Tumor necrosis factor receptor associated factor 6
(TRAF6) associates with TβRII and TβRI through the C-terminal TRAF domain and
forms lysine-63 (K63)-linked polyubiquitin chains (Yamashita et al., 2008). Unlike K48linked polyubiquitination, which generally targets proteins for degradation, K63-linked
polyubiquitin chains serve as scaffolds to assemble protein complexes and mediate their
activation (Haglund and Dikic, 2005). Polyubiquitinated TRAF6 recruits and activates
TGF-β-activated kinase 1 (TAK1), enabling the activation of downstream JNK or p38
MAPK via MKK4 or MKK3/MKK6 respectively (Sorrentino et al., 2008; Yamaguchi et
al., 1995). Interestingly, TRAF6 can be pulled down by TβRII in TβRI-deficient cells but
not by TβRI in TβRII-deficient cells, indicating that TRAF6-mediated JNK and p38
signaling is directly or indirectly through TβRII (Yamashita et al., 2008). Although TGFβ-induced JNK/p38 activation is independent from Smad activation, JNK/p38 cooperates
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with Smads to regulate apoptosis (Yu, Hebert, and Zhang, 2002). The JNK/p38 nonSmad pathway also plays a very important role in TGF-β-mediated EMT. Inhibition of
p38 activity using a p38 inhibitor blocked TGF-β-mediated changes in cell shape and
reorganization of the actin cytoskeleton (Bakin et al., 2002; Yu, Hebert, and Zhang,
2002).

Figure 1.6 Smad-independent (noncanonical) TGF-β signaling. Left panel: TGFβ activates p38 MAPK and JNK signaling through the activation of TAK1 by TRAF6.
TGF-β activates ERK signaling through recruitment and phosphorylation of
Shc. Middle panel: TGF-β activates RhoA and induces ubiquitin-mediated RhoA
degradation at tight junctions. Right panel: TGF-β induces PI3K/AKT signaling,
leading to the activation of mTOR and S6K1, and consequently to increased
translation.
The Small GTPase non-Smad pathway: The Rho-like GTPases, including
RhoA, Rac and Cdc42, play important roles in cytoskeletal organization and cell motility
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(Jaffe and Hall, 2005). In the small GTPase non-Smad pathway, RhoA is the key player
in TGF-β-induced EMT. TGF-β regulates RhoA activity in two different ways to induce
EMT: TGF-β initially induces a rapid activation of RhoA to induce actin stress fiber
formation (Bhowmick et al., 2001a; Edlund et al., 2002). However, after prolonged
signaling, TGF-β induces the assembly of TβRI-TβRII complexes at tight junctions,
where TβRII phosphorylates Par6, a scaffold protein regulating epithelial cell polarity.
Phosphorylated Par6 recruits Smurf1 to mediate localized ubiquitination and turnover of
RhoA at tight junctions (Ozdamar et al., 2005). TGF-β can also induce activation of
Cdc42 to induce morphological transformation in epithelial cells (Wilkes et al., 2003).
The PI3K/AKT non-Smad pathway: TGF-β has been shown to rapidly activate
PI3K, leading to activation of AKT (Bakin et al., 2000; Wilkes et al., 2005). The p85
regulatory subunit of PI3K was found to be constitutively associated with TβRII and only
associated with TβRI upon TGF-β stimulation (Yi, Shin, and Arteaga, 2005). The
activated PI3K/AKT pathway controls translational responses through mTOR/ S6 kinase
1(S6K) (Lamouille and Derynck, 2007). Activation of S6K is required for snail
expression, which works with Smad-mediated transcriptional responses during TGF-βinduced EMT (Pon et al., 2008). AKT can also directly interact with Smad3, resulting in
the inhibition of Smad3-mediated transcription, inhibit nuclear localization of FoxO
transcription factor thorough phosphorylation, and thereby protect cells from TGF-βinduced apoptosis and growth arrest (Chen et al., 1998; Conery et al., 2004; Seoane et al.,
2004; Shin et al., 2001) (Summarized in (Zhang, 2009)).
TGF-β signaling plays a dual role in tumor progression. At early stages of
tumorigenesis, TGF-β acts as a potent tumor suppressor due to its ability to inhibit the
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proliferation of epithelial cells. Mechanistically, Smad3/Samd4 complexes induce the
expression of cyclin-dependent kinase (CDK) inhibitors, such as p15 and p21 (Datto et
al., 1995; Hannon and Beach, 1994). P15 arrests cell cycle progression at the G1 phase
by abolishing the cyclin D-CDK4/6 interaction, while p21/p27 inhibits the cyclin ECDK2 complex and stops the cell cycle at the G1-S boundary (Siegel and Massague,
2003). TGF-β also suppresses c-Myc oncogene expression, which results in reduced cell
proliferation (Staller et al., 2001). TGF-β can also induce apoptosis in many cell types
(Jang et al., 2002; Ohgushi et al., 2005). Furthermore, TGF-β can inhibit tumor
progression by blocking the action of paracrine growth factors in the tumor stroma during
the early stages of tumor development (Bhowmick et al., 2004). However, at late stages
of tumorigenesis, tumors become resistant to the antiproliferative effects of TGF-β
through multiple mechanisms, including mutation or deletion of components of the TGFβ signaling pathway (Grady et al., 1999; Markowitz et al., 1995; Myeroff et al., 1995).
TGF-β can also promote tumor progression by inducing EMT and inactivating CD4+ and
CD8+ T-cells, and thereby facilitating tumor metastasis and invasion (Elliott and Blobe,
2005; Meulmeester and Ten Dijke, 2011). Imbalances in the activation status of Smaddependent versus Smad-independent TGF-β signaling might be the critical factor that
results in the switch in TGF-β signaling from tumor suppression to tumor promotion
(Zhang, 2009).
TGF-β is a potent inducer of EMT and treating various epithelial cells with TGFβ in culture is a common way to induce EMT. TGF-β can induce EMT through Smaddependent and Smad-independent signaling. TGF-β induces the expression of EMT
transcription factors, including the Snail, ZEB and basic helix-loop-helix (bHLH)
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families, through a direct Smad-dependent mechanism or indirectly through activation of
other transcription factors or relief of their repression by inhibitors. TGF-β also induces
the expression of microRNAs (miRNAs) to promote EMT. For example, miRNA-155
and miR-181a can be up-regulated by TGF-β-Smad signaling, and contribute to EMT
(Kong et al., 2008). EMT can also be induced by Smad-independent signaling pathways.
Hence, understanding different mechanisms in response to TGF-β may facilitate the
discovery of molecular targets in signaling leading to EMT. Identifying ways to suppress
EMT might ultimately inhibit tumor progression and metastasis.

1.4 HUMAN PAPILLOMAVIRUS (HPV) AND CERVICAL CANCER
Cervical cancer is the second most common malignancy among women worldwide. Although screening is very effective in preventing cervical cancer, approximately
500,000 new cases of cervical cancer are diagnosed and 280,000 deaths from this disease
occur annually (Peralta-Zaragoza et al., 2012). The main etiological agent for cervical
cancer is an infection with human papillomavirus (HPV). HPVs are small non-enveloped
viruses containing circular, double-stranded DNA (~ 8000 bps) that infect keratinocytes
of the skin or mucous membranes (Faridi et al., 2011). The HPV genome encodes six
early (E1, E2, E4, E5, E6 and E7) and two late (L1 and L2) proteins. The transcription of
the early and late genes is controlled by a non-coding long control region (LCR)
(Ganguly and Parihar, 2009). To date, more than 100 HPV types have been identified and
51 types infect the genital mucosa. HPVs can be classified into 3 subtypes according to
their association with cervical cancer: high-risk (oncogenic) types (currently including
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69, 73, 82), low-risk
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(nononcogenic) types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108) and probable
high-risk (26, 53, and 66) (Munoz et al., 2003; Schmitt et al., 2013). Most HPV infections
are asymptomatic and are cleared naturally. However, over 10% of the population cannot
clear high-risk HPV infections and this population stands to be at a high risk for
developing cervical cancer in the future (Grainge et al., 2005). Cervical cancer is a slowly
progressive disease. It starts with an infection to the genital mucosa by HPV which, when
the infection remains persistent, can progress through several stages of dysplasia called
Cervical Intraepithelial Neoplasia (CIN) before it develops into invasive cervical cancer
(Figure 1.7) (Saslow et al., 2012). Currently, two vaccines are available to prevent
infection by some HPV types: Gardasil (marketed by Merck) and Cervarix (marketed by
GlaxoSmithKline). Cervarix protect against infection with HPV type 16 and 18, which
cause 70% of cervical cancers. Gardasil protects against HPV type 16, 18 as well as 6 and
11, which cause 90% of genital warts (Toft et al., 2014).
It is now well accepted that a persistent cervical infection with high-risk HPV is
necessary for the development of cervical cancer. HPV16 is the most carcinogenic HPV
genotype, which accounts for 55%-60% of all cervical cancers; HPV18 is the second
most carcinogenic HPV genotype, which accounts for 10–15% of cervical cancers.
Approximately another 10 high-risk HPV genotypes contribute to the remaining 25–35%
of cervical cancers (de Sanjose et al., 2010; Munoz et al., 2003; Walboomers et al., 1999).
HPVs encode 8 genes, of which E6 and E7 are considered as oncoproteins and necessary
for malignant conversion. High-risk HPV E6 binds to E6-associated protein (E6-AP), a
cellular ubiquitin ligase, resulting in the ubiquitination and degradation of p53 (Werness,
Levine, and Howley, 1990). E7 binds to the retinoblastoma protein (Rb) tumor
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suppressor protein family which results in the release of the E2F transcription factor and
promotes cell proliferation (Dyson et al., 1989).

Figure 1.7 Progression of cervical lesions to cervical cancer. High risk HPV
infection can be cleared by the host immune system or become a persistent
infection. A persistent HPV infection can progress to LSIL, which can either
regress or progress to HSIL. HSIL is pre-cancerous, and still can regress or
progress to invasive cancer. Major early interventions include HPV vaccination
and the Pap test. The HPV vaccine protects against initial infection with HPV16
and 18, while the Pap test detects abnormal cytology in exfoliated cervical cells.

1.5 IN VITRO MODEL OF HPV16-MEDIATED TRANSFORMATION
To explore the cellular and molecular events associated with HPV-mediated
transformation, Pirisi et al established an in vitro model system to mimic the stages of
premalignant progression. Briefly, normal human keratinocytes (HKc) were isolated from
neonatal foreskin, and immortalized by transfection with a plasmid containing a head-totail dimer of HPV16 DNA (HKc/HPV16) and cultured in Keratinocyte serum-free
medium supplemented with epidermal growth factor (EGF) and bovine pituitary extract
16

(BPE). Growth factor-independent HKc (HKc/GFI) were selected by culturing
HKc/HPV16 in complete medium lacking EGF and BPE. Differentiation resistant cells
(HKc/DR) were further selected from HKc/GFI in complete medium containing 1 mM
calcium chloride and 5% fetal bovine serum (FBS) (Figure 1.8) (Pirisi et al., 1988; Pirisi
et al., 1987). HKc/DR are not tumorigenic, but they form squamous carcinomas in nude
mice upon transfection with activated Ras or Herpes Simplex Virus 2 (HSV2) DNA.
HKc/GFI and HKc/DR share several characteristics with cancer cells. For example:
HKc/GFI exhibit increased expression of the EGF receptor (EGFR) and constitutively
activative EGFR signaling, which contributes to their autonomous growth (Akerman et
al., 2001; Zyzak et al., 1994). HKc/DR are completely resistant to the antiproliferative
effects of TGF-β1 and TGF-β2 treatment, while HKc/HPV16 are as sensitive as normal
HKc to growth inhibition by TGF-β1 and TGF-β2 (Creek et al., 1995). The loss of
sensitivity to growth inhibition by TGF-β in HKc/DR is due at least in part to a partial
loss of TβRI (Mi et al., 2000). Smad activation induced by TGF-β in HKc/DR is about 50%
of the maximum levels of activation observed in HKc/HPV16. However, TGF-β
treatment of HKc/DR still results in EMT (Kowli et al., 2013). Retinoic acid (RA)
suppresses HKc/HPV16 cell growth (Creek et al., 1994; Pirisi et al., 1992), but HKc/DR
are resistant to RA-induced growth inhibition, and this resistance is linked to the loss of
sensitivity to TGF-β (Borger et al., 2000).
This model system was established by selection in vitro of cells representing a
more advanced transformed phenotype. Instead of radiation or treatment with
carcinogens, we have selected for growth factor-independent (GFI) and differentiation
resistant (DR) phenotypes using specialized culture conditions. This model represents
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distinct stages of transformation, including immortality, lack of requirement for growth
factors and lack of response to differentiation stimuli. It is valuable to identify genes
whose altered expression may contribute to transformation and in vitro progression by
comparing, using microarrays, gene expression profiles at the different stages. For
example, we compared gene expression between normal HKc and HKc/HPV16 and
between HKc/HPV16 and HKc/DR, and identified genes whose expression was altered
during early and late stages of in vitro progression. Among these we selected some genes
for further study, including, SIX1 (Wan et al., 2008). Thus, this in vitro model provides
us an excellent platform to study the cellular and molecular role that certain genes may
play during HPV16-mediated transformation.

Figure 1.8 In vitro model system of HPV16-mediated transformation.
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1.6 SUMMARY AND GOAL OF MY DISSERTATION RESEARCH.
Six1 overexpression has been found in various human cancers including tumors
of the breast (Coletta et al., 2008), ovary (Behbakht et al., 2007), cervix (Wan et al., 2008;
Zheng et al., 2010), colon (Ono et al., 2012) and liver (Ng et al., 2010). The
overexpression of Six1 is associated with increased tumor progression and metastasis,
and decreased survival (Christensen et al., 2008). For example, Six1 is overexpressed in
cervical cancer cell lines, and that the extent of Six1 overexpression is correlated to
increased tumor malignancy and lymph node metastasis (Tan, Zhang, and Qian, 2011;
Wan et al., 2008; Zheng et al., 2010). Six1 overexpression has been found to be
significantly associated with poorer overall survival in advanced-stage colorectal cancer
(CRC) (Ono et al., 2012). We previous performed gene expression analyses of HKc/DR
and HKc/HPV16, and determined that Six1 mRNA expression increased during in vitro
progression of HPV16-immortalized cells and that Six1 was overexpressed in about 23%
of cervical cancer samples in a tissue microarray (Wan et al., 2008). These findings
strongly suggest that Six1 might be involved in the progression of cervical premalignant
lesions to cervical cancer. However, the mechanism(s) by which Six1 promotes cervical
carcinogenesis and progression is still to be determined.
The main goal of this study is to explore the role of Six1 at both the early and
late stages of HPV16-mediated transformation by following the cellular and
molecular changes associated with the overexpression of Six1 in HKc/HPV16 and
HKc/DR. As an extension of these studies, we also investigated the role of Six1 on
tumor progression and metastasis in mouse and human colorectal cancer cell lines.
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CHAPTER 2
MATERIALS AND METHODS

Plasmid constructs
Total RNA was isolated from HKc/DR using the Total RNA Isolation Mini Kit
(Agilent, Wilmington, DE) according to the manufacturer’s protocol. The Six1 cDNA
was amplified using the Titan One Tube RT-PCR System (Roche, Indianapolis, IN). The
forward primer includes a NheI restriction site: 5’-GAC GCT AGC ATG TCG ATG
CTG CCG TCG TTT G-3’; the reverse primer contains a BamHI site: 5’-TAC GGA
TCC TGC TGC TCC AGG AAT CCC TTC G-3’. The restriction sites are shown in bold
and underlined. Human Six1 cDNA was then cloned into the NheI and BamHI site of the
mammalian expression vector pcDNA 3.1 (Invitrogen, Carlsbad, CA). The Six1 cDNA
insert sequence was verified by direct sequencing of both DNA strands. This construct is
referred to as pcDNA3.1-Six1. Mouse Six1 cDNA clone was purchased from Origene
(Rockville, MD), and then cloned into the EcoRI and NotI site of pcDNA3.1. This
construct is referred to as pcDNA3.1-mSix1.

HPV16-immortalized HKc cell lines and transfections
Normal HKc immortalized by transfection with HPV16 DNA (HKc/HPV16)
were cultured in keratinocyte serum free medium supplemented with epidermal growth
factor (EGF) and bovine pituitary extract (BPE) (Invitrogen) (Pirisi et al., 1987). This
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medium is referred to as complete medium. Growth factor-independent HKc (HKc/GFI)
cell lines were selected by culturing HKc/HPV16 in complete medium lacking EGF and
BPE. Differentiation resistant cells (HKc/DR) were further selected from HKc/GFI and
cultured in complete medium containing 1.0 mM calcium chloride and 5% fetal bovine
serum (FBS) (Pirisi et al., 1988).
HKc/HPV16 and HKc/DR were transfected with pcDNA3.1 or pcDNA3.1-Six1
using TransFast (Promega, Madison, WI) following the manufacturer’s instructions.
Stable transfectants, named HKc/HPV16-Ctrl, HKc/HPV16-Six1, HKc/DR-Ctrl and
HKc/DR-Six1 were selected in the presence of 50 µg/ml Zeocin (Invitrogen). HeLa cells
were cultured in Dulbecco’s Modification of Eagle’s Medium (DMEM) with 4.5 g/L
glucose (Mediatech, Manassas, VA) supplemented with 10% FBS (Atlanta Biologicals,
Lawrenceville, GA), and were transfected with pcDNA3.1 or pcDNA3.1-Six1 using
TransFast . Stable transfectants (HeLa-Ctrl and HeLa-Six1) were selected in the presence
of 300 µg/ml Zeocin.
For microarray analysis, HKc/DR-Ctrl and HKc/DR-Six1 were switched to
complete medium 48 h before RNA extraction. For cell differentiation resistance
experiments, HKc/HPV16-Ctrl and HKc/HPV16-Six1 were cultured with either complete
medium or complete medium supplemented with 1.0 mM calcium chloride or 5% FBS
for the indicated time.
MAPK inhibitors were dissolved in dimethyl sulfoxide (DMSO) and then diluted
in medium to a final concentration of 10 µM. Control cultures were exposed to equal
concentrations of DMSO (0.1%) with no inhibitors. Cells were treated for 48 h. All cells
were maintained in a humidified atmosphere of 5% CO2 and 95% air at 37 °C.
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Colorectal cancer cell lines
The C57BL/6-derived mouse colon adenocarcinoma cell line MC38 and the
human colon cancer cell lines HCT116, HT29 and SW80 were obtained from Dr. Maria
M. Peña (University of South Carolina, Columbia, SC). MC38 was cultured in DMEM
with 4.5 g/L glucose supplemented with 10% FBS. MC38 cells were transfected with
pcDNA3.1 or pcDNA3.1-mSix1 using Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions. Stable transfectants, named MC38-Ctrl and MC38-Six1,
were selected in culture medium containing 300 µg/ml Zeocin.
HCT116, HT29 and SW480 were maintained in RPMI-1640 medium
supplemented with 10% FBS. HT29 and SW480 human colon cancer cells were
transfected with pcDNA3.1 or pcDNA3.1-Six1 using FuGENE 6 (Promega). Stable
transfectants of HCT116 was selected in the presence of 200 µg/ml Zeocin, and referred
to as HCT116-Ctrl and HCT116-Six1. Stable transfectants of HT29 was selected in the
presence of 200 µg/ml Zeocin, and referred to as HT29-Ctrl and HT29-Six1. Stable
transfectants of SW480 was selected in the presence of 100 µg/ml Zeocin, and referred to
as SW480-Ctrl and SW480-Six1.

Real time PCR
Total RNA was isolated from cells using the Total RNA Isolation Mini Kit
(Agilent, Wilmington, DE) according to manufacturer’s protocol. Reverse transcription
was carried out with 1μg of total RNA using the iScript cDNA Synthesis Kit (BioRad,
Hercules, CA). Real time PCR was performed using iQ SYBR Green Supermix (BioRad)
following the manufacturer’s instructions. Primers are purchased from RealTimePrimers
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(Elkins Park, PA) or Integrated DNA Technologies (Coralville, IA). The sequence of the
primers used for real time PCR is shown in Table 2.1. β-actin was used as an internal
control. All samples were assayed in triplicate.
Table 2.1 Primer sequences used in RT-PCR. Primer sequence 5’– 3’.
Genes

Forward

Reverse

human Six1

ATT CTC ACC TCC CCA AAG TC

ACT TAG GAC CCC AAG TCC AC

human E-cadherin

TGC TCT TGC TGT TTC TTC GG

TGC CCC ATT CGT TCA AGT AG

human fibronectin

ACC AAC CTA CGG ATG ACT CG

GCT CAT CAT CTG GCC ATT TT

human N-cadherin

ACA GTG GCC ACC TAC AAA GG

CCG AGA TGG GGT TGA TAA TG

human occludin

ATG ACA AGC GGT TTT ATC CA

CTC CAG CTC ATC ACA GGA CT

human vimentin

GAG AAC TTT GCC GTT GAA GC

TCC AGC AGC TTC CTG TAG GT

human snail

ACC CCA CAT CCT TCT CAC TG

TAC AAA AAC CCA CGC AGA CA

human TβRI

CTT AAT TCC TCG AGA TAG GC

GTG AGA TGC AGA CGA AGC

human TβRII

GGT TCC TGT GTG CCC TTA TT

TGC AAC CCA TGA AGG TAA AA

human TβRIII

CTG GCC AGC TAC AGA GAG AG

ACC CTC AGA CAC CAA AAA CA

human β-actin

CGT GGA CAT CCG CAA AGA C

AGG GTG TAA CGC AAC TAA G

human CCL2

CAG CCA GAT GCA ATC AAT GCC

TGG AAT CCT GAA CCC ACT TCT

human CCL5

ATC CTC ATT GCT ACT GCC CTC

GCC ACT GGT GTA GAA ATA CTC C

human CSF-1

CAG AAG GAG GAC CAG CAA GTG A

GAT CCC TCG GAC TGC CTC TC

human CSF-2

CTC AGA AAT GTT TGA CCT CCA G

TGA CAA GCA GAA AGT CCT TCA G

Human VEGF

GAG ATG AGC T TC CTA CAG CAC

TCA CCG CCT CGG CTT GTC ACA T

Mouse HIF1α

GGT TCC AGC AGA CCC AGT TA

AGG CTC CTT GGA TGA GCT TT

Mouse HIF1β
mouse β-actin

TTT ATC CCT AGA GAT GGG TAC AGG

CCA CAG GCT GGA CAG AAA CC

AAG AGC TAT GAG CTG CCT GA

TAC GGA TGT CAA CGT CAC AC

mouse CXCL1

CCT TGA CCC TGA AGC TCC CT

CGG TGC CAT CAG AGC AGT CT

mouse CCL5

GCA AGT GCT CCA ATC TTG CA

GAT GTA TTC TTG AAC CCA CTT CTT CTC

mouse CSF-1

CAT CTC CAT TCC CTA AAT CAA C

ACT TGC TGA TCC TCC TTC C

mouse VEGF

GAG GAT GTC CTC ACT CGG ATG

GTC GTG TTT CTG GAA GTG AGC AA

Western blot analysis
Whole cells lysates were prepared with RIPA buffer (Pierce, Rockford, IL).
Antibodies against the following proteins were used: Six1, TβRI, TβRII, TβRIII,
23

aldehyde dehydrogenase 1 (ALDH1), β-catenin, cyclin E (1:1000, all from Santa Cruz
Biotechnology, Santa Cruz, CA), E-cadherin, fibronectin (1:10,000, both from BD
Biosciences, San Jose, CA), ERK, p-ERK, JNK, p-JNK, p38, p-p38, p-STAT3, cyclin D1,
vimentin (1:3000, all from Cell Signaling Technology, Danvers, MA), matrix
metalloproteinases (MMP)2, MMP9, proliferating cell nuclear antigen (PCNA), vascular
endothelial growth factor (VEGF) (1:1000, all from Abcam, Cambridge, MA).
For Triton X-100-soluble and -insoluble protein fractionation experiments, cell
extracts were prepared as previously described (Sadot et al., 1998). Briefly, HKc/HPV16Ctrl and HKc/HPV16-Six1 were plated in 6-well plates and cultured in complete medium
supplemented with 1.0 mM Ca2+ for the indicated times. The Triton X-100-soluble
fraction was extracted at room temperature with 200 μl of 0.5% Triton X-100, 2.5 mM
EGTA, 5 mM MgCl2, and 50 mM MES (pH 6.0) for 2 min. Then plates were washed
twice with the same buffer. The Triton X-100-insoluble fraction was scraped into 200 μl
of the same buffer. Equal volumes (20 μl) of cell fractionation extracts were separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Sera from MC38-Ctrl- and MC38-Six1- tumor bearing mice were analyzed by
Western blotting. Antibodies against the following proteins were used: MMP2, MMP9,
VEGF, HGF, interleukin (IL)-1β, LOX (1:1000, Abcam), TNFα, and IL-6 (1:1000, Cell
Signaling Technology).
The blots were incubated with primary antibody overnight at 4°C, washed three
times with PBST, followed by incubation with horseradish peroxidase (HRP)-conjugated
secondary antibody (1:10,000, Millipore, Temecula, CA). The blots were visualized with
ECL Prime Western Blotting Detection System (GE Healthcare, Buckinghamshire, UK)
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and exposed to BioMax light film (Kodak, Rochester, NY). As an internal control for
equal protein loading, blots were stripped and reprobed with antibody against β-actin
(Santa Cruz Biotechnology). Images were analyzed further using Image J software (NIH,
Bethesda, MD) to obtain a semi-quantitative assessment of band intensities.

Microarray analysis
Total RNA was isolated using the Agilent Total RNA Isolation Mini Kit
according to the manufacturer’s protocol. RNA quality was assessed using an Agilent
2100 Bioanalyzer and RNA Integrity Numbers (RIN) ranged from 9.8 to 10.0.
Microarray experiments were performed using the Agilent platform. Total RNA was
amplified and dye labeled using Agilent’s Low Input Quick Amp Labeling Kit (Agilent,
Wilmington, DE) according to the manufacturer’s instructions. Labeled RNA was then
purified using Qiagen’s RNeasy Mini Kit (Qiagen, Valencia, CA) and dye incorporation
and cRNA yield were assessed. Labeled cRNA samples were hybridized to Agilent
Whole Human Genome Microarrays 4x44K (Agilent, Wilmington, DE) using Agilent’s
Gene Expression Hybridization Kit (Agilent, Wilmington, DE) according to the
manufacturer’s instructions. Four vector control samples were hybridized against four
Six1 overexpression samples in a dye swap design. One slide was hybridized for
HKc/HPV16 and another slide for HKc/DR. After washes and drying, arrays were
scanned for both the Cy3 and Cy5 channels at 5 μm resolution using a ProScanArray
Express HT scanner (Perkin Elmer Life and Analytical Sciences) and the ScanArray
Express SP3 software. The scanned images were saved as TIFF files and fluorescence
intensities were quantitated using ImaGene 8.0.1 software (BioDiscovery). Raw
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intensities for backgrounds and foregrounds (spots) were uploaded into limmaGUI
(Wettenhall and Smyth, 2004) where features were background corrected using the
Normexp method with offset equal to 50 (Ritchie et al., 2007). Subsequently, data were
normalized within arrays using the locally weighted scatterplot smoothing (LOESS)
algorithm and between the arrays performing scale normalization. Normalized data (M
and A values) were exported from limmaGUI and normalized intensities for both Cy3
and Cy5 channel were calculated for all arrays by solving the equations for M and A,
using M = log2(R/G) and A = 1/2 [log2(R) + log2(G)]. R = Cy5 channel intensity (Red),
and G = Cy3 channel intensity (Green). In the final step, normalized intensities were
uploaded and analyzed using GeneSifter software (Geospiza, Inc.).

Immunofluorescence studies
Cells were plated in Lab-Tek II chambers (Nalge Nunc International, Rochester,
NY) for 24 h. Following fixation (with 4% paraformaldehyde in PBS, pH 7.2) and
permeabilization (with 0.1% Triton X-100 in PBS), samples were incubated with
antibodies against E-cadherin (1:200), β-catenin (1:100), fibronectin (1:200), TβRI
(1:100), TβRII (1:100) or TβRIII (1:100) overnight at 4°C. Samples were then washed
three times with PBST, followed by incubation with an Alexa 568-conjugated secondary
antibody (1:1000, Invitrogen). Nuclei were stained with 1:20,000 dilution of 4’, 6diamidino-2-phenylindole (DAPI) (Invitrogen) before cells were mounted. Slides were
viewed using either an Olympus X81 fluorescence microscope or a Zeiss LSM510
META confocal scanning laser microscope.
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Cells were plated in Lab-Tek II chambers (Nalge Nunc International, Rochester,
NY) for 24 h. Following fixation (with 4% paraformaldehyde in PBS, pH 7.2) and
permeabilization (with 0.1% Triton X-100 in PBS), samples were incubated with
antibodies against E-cadherin (1:200), β-catenin (1:100), fibronectin (1:200), TβRI
(1:100), TβRII (1:100) or TβRIII (1:100) overnight at 4°C. Samples were then washed
three times with PBST, followed by incubation with an Alexa 568-conjugated secondary
antibody (1:1000, Invitrogen). Nuclei were stained with 1:20,000 dilution of 4’, 6diamidino-2-phenylindole (DAPI) (Invitrogen) before cells were mounted. Slides were
viewed using either an Olympus X81 fluorescence microscope or a Zeiss LSM510
META confocal scanning laser microscope.

Cell invasion and migration assays (Transwell)
The invasive ability of HKc/HPV16-, HKc/DR- and MC38-Ctrl and

their

corresponding HKc/HPV16-, HKc/DR- and MC38-Six1 was measured using transwell
chambers (24 well plate) (Costar, Cambridge, MA) with polycarbonate membranes (8.0µm pore size) coated with 100 µl Matrigel (BD Biosciences, Franklin Lakes, NJ) on the
top side of the membrane. The upper surface of the matrix was plated with 20,000 cells,
and the cells were kept in basal medium containing 0.1% bovine serum albumin (BSA).
The lower chamber contained complete medium. After 24 h the cells were fixed and
stained with 0.1% crystal violet. Cells and Matrigel on the upper surface of the membrane
were carefully removed with a cotton swab. Enumeration of the cells that invaded
through the matrix was accomplished by visually counting cells in five randomly chosen
areas. Alternatively, crystal violet was extracted with ethanol and the absorbance
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determined in a spectrophotometer. The migration of cells was measured by directly
counting the cells in lower chamber. Each experiment was performed in triplicate wells
and repeated three times.

Wound healing (scratch) assay
MC38-Ctrl and MC38-Six1 cells were plated into 6-well plates and cultured until
approximately 90% confluent. Cell monolayers were wounded with a sterile 200 µl pipet
tip and then incubated with DMEM containing 1% FBS for 24 h or 48 h in a humidified
atmosphere of 5% CO2 and 95% air at 37 °C. Representative areas of wounded
monolayers containing wounds of the same width were marked and photographed under
an inverted microscope at 40× magnification. After incubation, the same areas were
photographed. The extent of wound repair was evaluated by measuring the area of the
wound by computerized image analysis using Image J software (NIH). Each experiment
was performed in triplicate wells and repeated three times.

Cell proliferation assay
To determine the growth rate of HKc/HPV16, HKc-Ctrl, HKc-Six1, HKc/DR,
HKc/DR-Ctrl and HKc/DR-Six1, 50,000 cells in 2 ml of their respective media were
plated per well in 6-well plates. Cells in triplicate wells were counted daily for up to 5
days of incubation at 37 °C, using a hemocytometer. For MC38, MC38-Ctrl and MC38Six1, 20,000 cells per well in 2 ml of DMEM containing 10% FBS were plated in 6-well
plates.
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Luciferase assays
HKc/HPV16-Ctrl, HKc/HPV16-Six1, HKc/DR-Ctrl and HKc/DR-Six1 were
seeded into 6-well plates. Transfections were performed using TransFast Transfection
Reagent (Promega) according to the manufacturer’s instructions. The luciferase construct
p6SBE-luc, which contains six copies of the Smad binding element (SBE) and p6SMEluc, which contains Smad mutated elements (SME) were obtained from Dr. Scott Kern
(Dai et al., 1998). For each well, cells were transfected with either p6SBE-luc (4 µg) or
p6SME-luc (4 µg), along with pRL-SV40 (4 ng) (Promega, Madison, WI) Renilla
luciferase as a control for transfection efficiency. Cells were treated with 40 pM TGF-β1
or vehicle 24 h after transfection. Both firefly and Renilla luciferase activity were
measured using the Dual Luciferase Assay Kit (Promega, Madison, WI) 48 h after
transfection. Firefly luciferase values were normalized to Renilla luciferase values.

Single-cell isolation from tumors
Tumors were dissected free of necrotic areas, connective tissue, and blood clots
then rinsed 3 times with cold (4°C) DMEM containing 1% FBS and 2% Pen/Strep.
Tumors were sliced into 1-3 mm3 fragments and then incubated in DMEM containing
collagenase type I (200 units/ml), DNase (270 units/ml), and hyaluronidase type IV (35
NF units/ml) (Sigma, St. Louis, MO for 30 min at 37 °C. The resulting cell suspension
was kept in wet ice, filtered through a 70 µm nylon cell strainer (BD Biosciences,
Bedford, MA), and washed twice with PBS.
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Flow cytometry analysis
HKc/DR-Ctrl and HKc/DR-Six1 were stained with FITC-conjugated anti-CD24
and PE-conjugated anti-CD44. MC38-Ctrl and MC38-Six1 were stained with FITCconjugated anti-CD44 and PE-conjugated anti-CD166. Single-cell suspensions isolated
from MC38-Ctrl or MC38-Six1 tumors were stained with eFluor450-conjugated antiCD45, APC-conjugated CD11b, FITC-conjugated anti-Gr1 and PE-conjugated anti-F4/80.
All the antibodies were purchased form eBioscience (San Diego, CA). One million cells
were incubated with antibodies in 100 μl wash buffer (PBS containing 0.1% BSA) at
4 °C for 1 h. Cells were then washed twice with ice-cold wash buffer, and fixed with 1%
paraformaldehyde. Flow cytomertry analysis was performed using a BD LSRII flow
cytometer (BD Biosciences, San Jose, CA), and 30,000 cells were analyzed.

In vitro tumorsphere formation assay
HKc/HPV16-Ctrl, HKc/HPV16-Six1, HeLa-Ctrl, HeLa-Six1, MC38-Ctrl and
MC38-Six1 (10,000 per well) were plated in ultra-low attachment 6-well plates (Corning,
Tewksbury, MA) in 2 ml serum-free DMEM/F12 media (Invitrogen) supplemented with
20 ng/ml EGF (Sigma, St. Louis, MO), 10 ng/ml basic fibroblast growth factor (bFGF,
Sigma), 5 μg/ml insulin (Sigma), 1×B27 supplement (Invitrogen) and 0.4% bovine serum
albumin (BSA, Sigma). Cells were cultured under 5% CO2 at 37°C for 7 days.

Xenograft mouse model
Eight-week-old female athymic nude (nu/nu) mice were purchased from The
Jackson Laboratory (Bar Harbor, Maine). Briefly, 5×106 HKc/DR-Ctrl or HKc/DR-Six1
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cells were suspended in 100 μl of serum-free medium containing 50% Matrigel, and
injected subcutaneously into the flank of nude mice. For HeLa, 3×106 HeLa-Ctrl or
HeLa-Six1 were injected into each side of the flank of nude mice. Six weeks after
implantation, mice were sacrificed and the tumor weights were measured.

Homograft mouse model
For the orthotopic model, MC38-Ctrl and MC38-Six1 were harvested and washed
with PBS just prior to implantation. Eight-week-old male and female syngeneic C57BL/6
mice were anesthetized by inhalation of 2% isoflurane in oxygen. A midline incision was
made to expose the cecum. Then, 10 μl of PBS containing 2×106 MC38-Ctrl or MC38Six1 cells were injected into the cecum subserosa using a 33-gauge micro-injector
(Hamilton Company, Reno, NV). The injection site was sealed with a tissue adhesive
(3M, St. Paul, MN) and washed with 70% alcohol and PBS to eliminate the leakage of
the cancer cells. The cecum was replaced in the peritoneal cavity, and the abdominal wall
and skin closed with 6-0 polyglycolic acid sutures (CP Medical, Portland, OR). Six
weeks after implantation, mice were sacrificed. Tumor weights were measured, and
tumors were processed for further analysis.
For the subcutaneous model, 2×106 MC38-Ctrl or MC38-Six1 cells were
suspended in 100 μl of PBS, and injected subcutaneously into the flank of C57BL/6 mice.
Six weeks after implantation, mice were sacrificed and tumors were stripped and
weighted.
For the splenic metastasis model, eight-week-old syngeneic C57BL/6 mice were
anesthetized by inhalation of 2% isoflurane in oxygen. A lateral incision was made to

31

expose the spleen. Ten microliters of PBS containing 2×105 MC38-Ctrl or MC38-Six1
cells were injected into the spleen using a 33-gauge micro-injector. The injection site was
pressed using a cotton swab to stop bleeding, sealed with a tissue adhesive and washed
with PBS to eliminate the leaked cancer cells. The spleen was replaced and the
abdominal wall and skin closed with 6-0 polyglycolic acid sutures. Three weeks after
implantation, mice were sacrificed and spleens and livers were collected and weighted.

Histology and immunohistochemistry
Tumors were fixed and embedded in paraffin, 5 μm sections were obtained and
stained with hematoxylin and eosin (H&E) (VWR, West Chester, PA) for visual
examination.
Tumor sections were deparaffinized, rehydrated, then incubated in a microwave
oven with 0.01 M citrate buffer, pH 6.0 for 10 min for antigen retrieval. Endogenous
peroxidases were blocked with 3 % H2O2 for 15 min. Nonspecific epitopes were blocked
with horse serum (Jackson ImmunoResearch, West Grove, PA) for 1 h. The sections were
incubated overnight at 4°C with antibodies against one of the following proteins: PCNA
(1:300, abcam), CD31, LOX, MMP9, α-SMA, VEGF, vascular endothelial growth factor
receptor 1 (VEGFR1) (1:100, abcam), cleaved caspase 3 (1:100, Cell Signaling
Technology), Six1, ALDH1, (1:100, Santa Cruz), and Ki67 (1:100, OriGene). After
incubation with a HRP-conjugated secondary antibody

(BioRad) for 1 h at room

temperature, antigen signals were detected using the 2-Solution Diaminobenzidine (DAB)
Kit (Invitrogen), counterstained with hematoxylin, mounted in Acrymount (StatLab,
Mckinney, TX), and visualized under a light microscope.
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Statistical Analysis
Data were expressed as the mean  standard deviation (SD). Statistical analysis
was performed using the students’ t-test when only two value sets were compared, and
one-way ANOVA followed by Dunnett’s test when the data involved three or more
groups. P < 0.05, P < 0.01 or P < 0.001 were considered statistically significant and
indicated in the figures by *, ** or *** respectively.
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CHAPTER 3
SIX1 PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION AND MALIGNANT
CONVERSION IN HKC/DR

3.1 INTRODUCTION
In our in vitro model for HPV-mediated carcinogenesis, normal human
keratinocytes (HKc) immortalized by transfection with HPV16 DNA (HKc/HPV16)
progress toward malignancy through growth factor-independent (HKc/GFI) and
differentiation-resistant (HKc/DR) stages (Pirisi et al., 1988). Although immortalized and
differentiation resistant, HKc/DR are not tumorigenic (Pirisi et al., 1988). Gene
expression profiling studies determined that Six1 is overexpressed in HKc/DR.
Furthermore, Six1 was overexpressed in 23% of cervical cancer samples in a tissue
microarray (Wan et al., 2008). These findings prompted us to further investigate the role
of Six1 overexpression in HPV16-mediated transformation.
The Six1 homeoprotein, a member of the Six family of homeodomain
transcription factors, is essential for the development of numerous organs (Ikeda et al.,
2010; Xu et al., 2003; Zheng et al., 2003). Six1 overexpression has been found in various
human cancers including tumors of the breast (Coletta et al., 2008), ovary (Behbakht et
al., 2007), cervix (Wan et al., 2008; Zheng et al., 2010) and liver (Ng et al., 2010). Six1
overexpression is associated with increased tumor progression and metastasis, and
decreased survival (Christensen et al., 2008). For example, Six1 overexpression in human
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breast cancer cell lines induced epithelial-mesenchymal transition (EMT) and metastasis,
which was associated with Smad-dependent transforming growth factor-β (TGF-β)
signaling and increased TGF-β receptor type I (TβRI) expression (Micalizzi et al., 2009;
Micalizzi et al., 2010). SIX1 mRNA expression increased during in vitro progression of
HPV16-immortalized cells and Six1 protein is overexpressed in cervical cancer tissues,
which strongly suggests that Six1 might be involved in the progression of cervical
premalignant lesions to cervical cancer (Wan et al., 2008). Six1 is also overexpressed in
cervical cancer cell lines, and the extent of Six1 overexpression correlates to increased
tumor malignancy and lymph node metastasis (Tan, Zhang, and Qian, 2011; Wan et al.,
2008; Zheng et al., 2010). However, the mechanisms by which Six1 promotes cervical
carcinogenesis and progression remain to be determined.
In this study we explored the functional consequences of Six1 overexpression in
HKc/DR. HKc/DR overexpressing Six1 exhibited a more mesenchymal phenotype
compared to vector controls, including a fibroblastic appearance and increased motility
and invasion. Induction of EMT by overexpression of Six1 was associated with decreased
activity of Smad-dependent signaling and activation of the mitogen-activated protein
kinase (MAPK) pathway. In particular, we observed increased activity of p38 MAPK and
increased expression of the TβRII upon Six1 overexpression. Moreover, we determined
that overexpression of Six1 in HKc/DR resulted in malignant conversion which was
associated with an increase in the population of cancer stem cell (CSC)-like cells. We
conclude that Six1 overexpression in HKc/DR induces EMT and promotes tumorigenesis
by activation of p38-TβRII signaling.
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3.2 RESULTS
3.2.1 THE EXPRESSION OF SIX1 INCREASES DURING HPV16-MEDIATED
TRANSFORMATION OF HKC
Previous studies in our laboratory using gene expression profiling discovered that
SIX1 mRNA increased during in vitro progression of HKc/HPV16 toward the HKc/DR
phenotype (Wan et al., 2008). To further validate overexpression of Six1 during in vitro
progression of HPV16-immortalized HKc, we conducted both real time PCR and
Western blot analysis for Six1 in three sets of HKc/HPV16 and HKc/DR lines
(designated D1, D4 and D5), derived from normal HKc isolated from three different
foreskins.

Figure 3.1 The expression of Six1 increases during in vitro progression of HPV16immortalized human keratinocytes. (A) Real-time PCR analysis of Six1 mRNA in
three independently derived HKc/HPV16 (HKc) lines (D1, D4 and D5) and their
corresponding HKc/DR (DR) lines. Six1 expression was normalized to β-actin. (B)
Top: western blot for Six1 in HKc/HPV16-D1, -D4 and -D5, (labeled as HKc) and
their corresponding HKc/DR (labeled as DR). β-actin was used as control for equal
protein loading. Bottom: the expression of Six1 protein was quantified by using
ImageJ software. Bars indicate standard deviation (SD) and *** indicate statistically
significant p value < 0.001.
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The results showed that the expression of both Six1 mRNA (Figure 3.1A) and
protein (Figure 3.1B) increased in HKc/DR compared to HKc/HPV16.

3.2.2

OVEREXPRESSION

OF

SIX1

INDUCES

ALTERATIONS

IN

CELL

MORPHOLOGY AND BEHAVIOR
HKc/DR stably overexpressing Six1 were established by transfection of HKc/DR
(referred to as HKc/DR-Six1) with pcDNA3.1-Six1. Controls (referred to as HKc/DRCtrl) were HKc/DR transfected with pcDNA3.1. Western blots confirmed that HKc/DRSix1 overexpressed Six1 protein (Figure 3.2A). HKc/DR-Six1 exhibited an elongated and
fibroblastic appearance rather than the typical cobblestone epithelial-like morphology of
HKc/DR-Ctrl (Figure 3.2B). The overexpression of Six1 in HKc/DR increased cell
migration approximately 2.6-fold and cell invasion through Matrigel by 6.5-fold (Figure
3.2C). Six1 overexpression inhibited cell proliferation (Figure 3.2D). These data
demonstrate that HKc/DR overexpressing Six1 exhibited a much more mesenchymal
phenotype with increased migration and cell invasion properties compared to the vectortransfected controls.

3.2.3 SIX1 OVEREXPRESSION IN HKC/DR PROMOTES EMT
We next explored the effects of Six1 overexpression on global gene expression
using Agilent Whole Human Genome Microarrays (4x44K). Paired comparisons of gene
expression were made between four individual clones of HKc/DR-Ctrl and HKc/DR-Six1.
We used Gene Sifter software to analyze the microarray results.

37

Figure 3.2 Six1 overexpression in HKc/DR induces EMT-like characteristics. (A)
HKc/DR were stably transfected with either pcDNA3.1 (DR-Ctrl) or pcDNA3.1-Six1
(DR-Six1). Six1 protein levels in cell extracts were determined by western blotting. βactin was used as a loading control. (B) Cell morphology of HKc/DR-Ctrl (DR-Ctrl)
and HKc/DR-Six1 (DR-Six1). Images are shown at 100× magnification. (C) Invasion
(upper panels) and migration (lower panels) assays for HKc/DR-Control (DR-Ctrl)
and HKc/DR-Six1 (DR-Six1). Images for the invasion assay are shown at 400× and
those for migration at 100× magnification. Quantification of the invasion assay and
the migration assay are shown in the upper right and lower rights panels, respectively.
Bars indicate SD, and *** indicate statistically significant p values < 0.001. (D) Cell
proliferation was determined by directly counting cells at the days indicated in
HKc/DR (DR), HKc/DR-Six1 (DR-Six1), and HKc/DR-Ctrl (DR-Ctrl).
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To determine the differentially expressed genes in the pairwise comparisons we
used a fold change greater than 1.5 and a p-value smaller than 0.05 as cutoff values. In
addition, KEGG pathways analysis was performed on the differentially expressed genes.
We noted that a number of EMT related genes were changed in SIX1-overexpressing
HKc/DR. We used Cluster and TreeView software to analyze genes involved in cell-cell
junctions and a series of markers associated with EMT in HKc/DR-Ctrl and HKc/DRSix1 (Figure 3.3A). We found that, in response to Six1 overexpression, cell-cell junctions
and EMT markers were altered, including decreased expression of epithelial-related
genes, such as E-cadherin (CDH1) and occludin (OCLN), and increased expression of
mesenchymal-related genes, such as fibronectin (FN1), N-cadherin (CDH2) and vimentin
(VIM), as well as increased expression of transcription factors that promote EMT, such
as snail (SNAI1), twist1 and ZEB2 (Figure 3.3A). These microarray data suggest that
Six1 overexpression induces EMT in HKc/DR.
Real time PCR was used to confirm selected gene expression changes identified
by microarrays. As shown in Figure 3.3B, the mRNA level of E-cadherin and occludin
decreased by 86% and 84% respectively, while mRNA levels of fibronectin, N-cadherin,
vimentin and snail increased by 5.1-, 10.5-, 10.6- and 4.0-fold respectively in HKc/DRSix1 compared to HKc/DR-Ctrl. Furthermore, we examined the protein levels of Ecadherin (an epithelial maker) and fibronectin (a mesenchymal marker) by western blot
analysis and immunofluorescence. The results showed changes in protein levels that
corresponded with what we observed at the mRNA level (Fig 3.3C). We also investigated
β-catenin, because it is a key component of adherens junctions in epithelial cells (Schock
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and Perrimon, 2002), and we found that the expression of β-catenin decreased in cells
overexpressing Six1 (Fig 3.3C).

Figure 3.3 Six1 overexpression induces markers of EMT in HKc/DR. (A) Hierarchical
clustering of differentially expressed genes involved in cell-cell junctions and EMT
between HKc/DR-Ctrl (DR-Ctrl) and HKc/DR-Six1 (DR-Six1) was conducted using
cluster and TreeView software. The color represents the expression level of a gene
above (red), below (green), or at (black) the mean expression level of that gene across
all samples. (B) Levels of mRNA expression of E-cadherin, occludin, fibronectin, Ncadherin, vimentin and snail were determined by Real time PCR in HKc/DR-Ctrl
(DR-Ctrl) and HKc/DR-Six1 (DR-Six1). Data were normalized to β-actin expression.
Bars indicate SD, and ** and *** indicate statistically significant p values < 0.01 and
0.001 respectively. (C) Left panel: western blot for Six1, fibronectin, E-cadherin and
β-catenin in HKc/DR-Ctrl (DR-Ctrl) and HKc/DR-Six1 (DR-Six1). β-actin was used
as loading control. Right panels: immunofluorescent staining of E-cadherin (red) and
fibronectin (red) merged with nuclei (blue) in HKc/DR-Ctrl (DR-Ctrl) and HKc/DRSix1 (DR-Six1). Images are shown at 400× magnification.
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Since the distribution of E-cadherin and β-catenin is critical for functional
organization of adherens junctions, we used confocal microscopy to compare cellular
localization and overall levels of E-cadherin, β-catenin and fibronectin in HKc/DR-Six1
to that found in HKc/DR-Ctrl. The results show a dramatic downregulation of E-cadherin
and β-catenin, and increased levels of fibronectin in HKc/DR-Six1, which is a hallmark
of EMT (Figure 3.4). Taken together, our data show that Six1 overexpression promotes
EMT at the late stage of HPV16-mediated transformation.

Figure 3.4 Immunofluorescent staining of E-cadherin, β-catenin and fibronectin (red)
in HKc/DR-Ctrl (DR-Ctrl) and HKc/DR-Six1 (DR-Six1). Nuclei were stained with
DAPI (blue). Images were taken using a confocal microscope and are shown at 400×
magnification.
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3.2.4 INCREASED LEVELS OF TGF-Β RECEPTORS ARE ASSOCIATED WITH
SIX1 OVEREXPRESSION
Since Six1 overexpression induced EMT in HKc/DR, we attempted to identify the
signaling pathways regulated by Six1 that might be involved in promoting EMT. The
TGF-β pathway has been found to be dysregulated at early stages of cervical cancer
(Noordhuis et al., 2011), and TGF-β is a potent inducer of EMT in HKc/DR (Kowli et al.,
2013). Numerous EMT-associated genes regulated by TGF-β have been identified
(summarized in (Wendt, Allington, and Schiemann, 2009)). Therefore, we further
analyzed our microarray data for those genes involved in TGF-β signaling. In response to
Six1 overexpression, we observed altered expression of EMT associated genes targeted
by TGF-β such as increased Dab2, Hic5, vimentin, N-cadherin, urokinase plasminogen
activator (uPA), α-SMA, β3 integrin, and decreased E-cadherin, indicating that Six1induced EMT may be associated with activation of TGF-β signaling (Table 3.1).
Table 3.1. Expression of EMT-associated Genes Targeted by TGF-β in HKc/DR
Genes

Direction

Ratio

p‐value

E‐cadherin
β3 integrin
N‐cadherin
Vimentin
α‐Smooth Muscle Actin
Fibronectin
Urokinase Plasminogen Activator
Dab2
Hic5

Down
Up
Up
Up
Up
Up
Up
Up
Up

6.00
3.29
5.33
11.68
1.65
5.10
4.27
1.79
1.57

0.0000318
0.000146
0.0000291
0.000035
0.000736
0.0000709
0.0000149
0.006232
0.001866

Three receptors, TGF-β receptor type I, type II and type III (TβRI, TβRII and
TβRIII), are involved in TGF-β signaling (Meulmeester and Ten Dijke, 2011). Two of
the TGF-β receptors were upregulated in HKc/DR overexpressing Six1. Real time PCR

42

showed upregulation of TβRII mRNA by about 2.4-fold and TβRIII expression by 6.6fold in DR-Six1 compared to DR-Ctrl (Figure 3.5A). TβRI mRNA increased by about
1.7-fold in DR-Six1, but that change was not statistically significant (Figure 3.5A).
Western blotting and immunofluorescence analysis determined increased protein levels
of TGF-β receptors, consistent with the changes in mRNA levels (Figure 3.5B).

Figure 3.5 Six1 overexpression in HKc/DR increases the expression of TβRs. (A)
Levels of mRNA expression of TβRI, TβRII and TβRIII were determined by real time
PCR in HKc/DR-Ctrl (DR-Ctrl) and HKc/DR-Six1 (DR-Six1). Data were normalized
to β-actin expression. Bars indicate SD and *** indicate statistically significant p
values < 0.001. (B) Left panel: western blot analysis of TβRI, TβRII and TβRIII in
HKc/DR-Ctrl (DR-Ctrl) and HKc/DR-Six1 (DR-Six1). β-actin was used as control for
equal protein loading. Right panels: immunofluorescent staining of TβRI, TβRII and
TβRIII (red) in HKc/DR-Ctrl (DR-Ctrl) and HKc/DR-Six1 (DR-Six1). Nuclei were
stained with DAPI (blue). Images are shown at 630× magnification.
Taken together, our results show that Six1 overexpression leads to enhanced
expression of the TGF-β receptors, especially TβRII and TβRIII, which might contribute
to activation of TGF-β signaling.
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3.2.5 SMAD-DEPENDENT TGF-Β SIGNALING IS NOT ACTIVATED IN
ASSOCIATION WITH SIX1
We next investigated whether increased TGF-β receptors are linked to enhanced
canonical TGF-β signaling in DR-Six1. We analyzed basal phosphorylation of Smad2/3
in DR-Ctrl and DR-Six1 by western blotting. Smad2/3 phosphorylation was decreased in
Six1 overexpressing cells, suggesting decreased basal canonical TGF-β signaling (Fig
3.6A). To further explore whether Six1 overexpression altered Smad-dependent signaling,
we also compared the activity of a Smad-responsive luciferase reporter construct
(p6SBE-Luc) in DR-Ctrl to DR-Six1. Overexpression of Six1 decreased somewhat the
basal activity of the Smad-responsive luciferase reporter (Fig 3.6B Top Panel). There was
also no difference in fold-induction of the Smad-dependent reporter construct between
DR-Ctrl (Fig 3.6B Middle Panel) and DR-Six1 (Fig 3.6B Bottom Panel) in response to
TGF-β1 treatment. These data suggest that Six1 neither increases endogenous Smaddependent signaling, nor enhances the activation of Smad-dependent signaling in
response to TGF-β1 treatment.

3.2.6 P38 MAPK SIGNALING CONTRIBUTES TO SIX1-INDUCED EMT
Besides Smad-dependent signaling, TGF-β acts through a variety of Smadindependent signaling pathways, including: (1) MAP kinase (MAPK) pathways, such as
ERK1/2, p38 MAPK and JNK; (2) PI3K/AKT pathways; and (3) Rho-like GTPase
signaling pathways (Zhang, 2009). Thus, we investigated Smad-independent TGF-β
signaling in HKc/DR-Ctrl and HKc/DR-Six1 by Western blotting using phospho-specific
antibodies for p-ERK, p-p38, p-JNK, p-AKT, and p-PI3K p85.
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Figure 3.6 Six1 overexpression in HKc/DR activates Smad-independent pathways.
(A) Phospho-Smad2/3 was detected by western blot analysis in cell extracts prepared
from HKc/DR-Ctrl (DR-Ctrl) and HKc/DR-Six1 (DR-Six1). (B) Upper panel:
HKc/DR-Ctrl and HKc/DR-Six1 were co-transfected with a TGF-β-inducible
luciferase reporter (p6SBE-luc), which contains six tandem copies of the Smad
binding element (SBE), and pRL-SV40 Renilla luciferase, as control for transfection
efficiency. Luciferase activity was determined 48 h after transfection. Firefly
luciferase values are normalized to Renilla luciferase. Bars indicate SD.
Middle/Lower panels: HKc/DR-Ctrl or HKc/DR-Six1 were transfected with either
p6SBE-luc or p6SME-luc, which contains mutated SBEs (SME). Twenty four h after
transfection cells were treated with 40 pM TGF-β1 for 24 h and then luciferase
activity was determined. Values are normalized to Renilla luciferase. Bars indicate
SD. (C) Protein levels of p-ERK, ERK, p-p38, p38, p-JNK and JNK were determined
by western blotting in HKc/DR-Ctrl (DR-Ctrl) and HKc/DR-Six1 (DR-Six1). (D)
Western blot of p-AKT (Tyr326), p-AKT (Ser473) and p-PI3-kinase p85
(Tyr467/199) in HKc/DR-Ctrl (DR-Ctrl) and HKc/DR-Six1 (DR-Six1). β-actin was
used as a loading control.
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As shown in Figure 3.6C, Six1 overexpression resulted in a dramatic increase in
phosphorylation of ERK, p38, and JNK in HKc/DR-Six1. In contrast, overexpression of
Six1 resulted in decreased phosphorylation of AKT and PI3K p85, indicating Six1
overexpression in HKc/DR repressed the PI3K/AKT pathway (Figure 3.6D). Collectively,
these data suggest activation of MAPKs but not PI3K/AKT upon Six1 overexpression in
HKc/DR. ERK1/2, JNK and p38 activation has been reported to induce EMT in various
cancers (Zhang, 2009). We next investigated which MAPK played a dominant role in
Six1-induced EMT by treating HKc/DR-Six1 with MAPK inhibitors. Treatment of
HKc/DR-Six1 with the p38 inhibitor SB202190 blocked several markers of Six1-induced
EMT, increasing E-cadherin mRNA and reducing mRNA levels of fibronectin and snail
(Figure 3.7A). In contrast, treatment of HKc/DR-Six1 with the ERK inhibitor U0126 did
not block Six1 modulation of mRNA markers of EMT, and the JNK inhibitor SP600125
increased mRNA levels of E-cadherin, but did not decrease fibronectin or snail mRNA
(Figure 3.7A).
Similar to what was observed at the mRNA level, SB202190, but not U0126 or
SP600125, decreased fibronectin protein expression and slightly increased E-cadherin
protein level in HKc/DR-Six1 (Figure 3.7B). Moreover, inhibition of p38 by SB202190
treatment in HKc/DR-Six1 decreased the expression of TβRII mRNA by about 38%, but
had no effect on the expression of TβRI or TβRIII mRNA (Figure 3.7C). HKc/DR-Six1
treated with SB202190, but not U0126 or SP600125, lost some of their fibroblastic
appearance (Figure 3.7D).
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Figure 3.7 Six1 overexpression in HKc/DR activates p38-TβRII signaling. (A)
HKc/DR-Six1 were treated with the ERK inhibitor U0126 (10 μM), the p38
inhibitor SB202190 (10 μM), the JNK inhibitor SP600125 (10 μM) or DMSO for
48 h. mRNA expression of E-cadherin, fibronectin and snail was then determined
by real time PCR. Data were normalized to β-actin expression. (B) Western blot
analysis for E-cadherin, fibronectin and β-actin (loading control) after treatment of
HKc/DR-Six1 for 48 h with U0126 (10 μM), SB202190 (10 μM), SP600125 (10
μM) or DMSO. (C) mRNA levels of TβRI, TβRII and TβRIII were determined by
real time PCR after treatment of HKc/DR-Six1 with 10 μM SB202190 for 48 h.
Data were normalized to β-actin expression. Bars indicate SD, and ** and ***
indicate p values < 0.01 and < 0.001 respectively. (D) Phase-contrast photographs
of HKc/DR-Six1 treated with U0126 (10 μM), SB202190 (10 μM), SP600125 (10
uM) or DMSO for 48 h. Images are shown at 200× magnification. (E) Invasion
assays for HKc/DR-Six1 treated with DMSO or SB202190 (10 μM for 24 h). Cell
invasion was determined by a Matrigel invasion assay. Images are shown at 100×
magnification. The number of invading cells was quantified after crystal violet
staining. Quantification of the invasion assay is presented in the bar graph next to
the photographs. Each column represents the mean of three repeats.
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Lastly, HKc/DR-Six1 treated with SB202190 exhibited a decreased ability to
invade through Matrigel (Figure 3.7E). These results support the conclusion that p38
MAPK signaling plays an important role in promoting EMT in Six1 overexpressing
HKc/DR.

3.2.7. OVEREXPRESSION OF SIX1 RESULTS IN MALIGNANT CONVERSION IN
HKC/DR AND LARGER TUMORS IN HELA
Next, we tested whether overexpression of Six1 in the non-tumorigenic HKc/DR
resulted in malignant conversion. We found that HKc/DR-Six1 formed tumors in nude
mice (7 out of 10 mice), whereas HKc/DR-Ctrl failed to form tumors (0 out of 10 mice)
(Figure 3.8A). Histologic examination indicated high-grade squamous cell carcinoma,
characterized by poor differentiation and high mitotic activity (Figure 3.8B). We detected
by immunohistochemistry the expression of Six1 in the tumors as well as Ki67 and
PCNA (markers of cell proliferation) (Figure 3.8B). We also dissected the tumor tissue,
isolated tumor cells and then cultured the tumor cells in vitro: these cells exhibited
similar fibroblastic-like morphology as HKc/DR-Six1 (Figure 3.9A), and showed even
higher levels of Six1 mRNA than HKc/DR-Six1 (Figure 3.9B).
We also used the human cervical cancer cell line HeLa to explore the enhanced
tumorigenic properties associated with Six1 overexpression. We found that HeLa stably
overexpressing Six1 (HeLa-Six1) formed larger tumors in nude mice as compared to
vector controls (HeLa-Ctrl) (Figure 3.8C). Since the increased tumor size may be caused
by increased proliferation or decreased apoptosis, we compared the cell proliferation
marker Ki67 and the apoptosis marker cleaved caspase 3 in HeLa-Ctrl and HeLa-Six1.
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Figure 3.8 Six1 overexpression promotes tumorigenesis. (A) Six1-overexpressing
HKc/DR form aggressive tumors in vivo. Upper panel: Six1-overexpressing HKc/DR
(DR-Six1) or controls (DR-Ctrl) were injected into the flank of nude mice for 6
weeks. Tumors arose in HKc/DR-Six1, but not in HKc/DR-Ctrl. Middle panel: Six1induced tumors. Lower panel: tumor incidence rates in HKc/DR-Six1 and HKc/DRCtrl groups (n=10). (B) Histology of tumors formed by Six1-overexpressing HKc/DR.
H&E-stained sections of HKc/DR-Six1 tumors (upper left), the expression of Six1
(Upper right), Ki67 (lower left) and PCNA (lower right) in DR-Six1 tumors by
immunohistochemistry (X400). (C) Upper panel: Six1-overexpressing HeLa (HeLaSix1) were injected into the right flank of nude mice, and vector controls (HeLa-Ctrl)
were injected into the left flank for 6 weeks. The weight of tumors in HeLa-Six1
group increases as compared to that in HeLa-Ctrl group. Lower panel: tumors formed
from HeLa-Six1 (upper) and HeLa-Ctrl (lower). (D) The expression of Six1, Ki67 and
cleaved caspase 3 in tumors from HeLa-Ctrl and HeLa-Six1. (X400)
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Figure 3.9 Cells isolated from HKc tumors. (A) Cell morphology of HKc/DR-Six1
(DR-Six1) and cells isolated from tumors (HKc tumor) cultured in DR medium or
DMEM medium. Images are shown at 100× magnification. (B) mRNA expression of
Six1 in HKc/DR-Ctrl (DR-Ctrl), HKc/DR-Six1 cultured in HKc/DR medium (DRSix1-HKc), cells isolated form HKc/DR-Six1 tumor that cultured in HKc/DR medium
(passage 3) (DR-Six1-Tumor-P3) and cells isolated form HKc/DR-Six1 tumor that
cultured in HKc/DR medium (passage 1) (DR-Six1-Tumor-P1) was determined by
real time PCR.
Tumors overexpressing Six1 (HeLa-Six1) showed a greater percentage of Ki67
positive cells compared to controls (HeLa-Ctrl) (Figure 3.8D), indicating Six1 enhanced
tumor cell proliferation in vivo. There was no marked difference in the expression of
cleaved caspase 3 between tumors from HeLa-Six1 and HeLa-Ctrl (Figure 3.8D),
suggesting the effect of Six1 on tumor growth is associated with increased cell
proliferation rather than alterations in apoptosis.

3.2.8 SIX1 OVEREXPRESSION INDUCES FEATURES OF CANCER STEM CELLS
Cancer stem cells (CSCs) are proposed to drive tumor onset and maintain tumor
progression. TGF-β signaling has been known to play a vital role in regulating CSCs by
induction of EMT (Mani et al., 2008). Therefore, we analyzed CSC markers in HKc/DR50

Ctrl and HKc/DR-Six1. Cell surface antigens CD44+/CD24- have been widely used as
breast and ovarian cancer CSCs markers (Meng et al., 2012; Sheridan et al., 2006), and
have recently been identified as cervical CSCs markers (Gu et al., 2011). Another
important stem cell marker is aldehyde dehydrogenase 1 (ALDH1) (Rao et al., 2012; Yao
et al., 2011). We thus measured CD44+/CD24- populations and the expression level of
ALDH1 in HKc/DR-Ctrl and HKc/DR-Six1 by flow cytometry. HKc/DR-Six1 had a
markedly increased CD44+/CD24- population (86% in HKc/DR-Six1 versus 11% in
HKc/DR-Ctrl) (Figure 3.10A) and increased ALDH1 expression as compared to
HKc/DR-Ctrl (Figure 3.10B). To determine whether Six1 also enhances characteristics of
CSCs in HeLa, we examined tumorsphere formation ability of HeLa-Ctrl and HeLa-Six1.
As shown in Figure 3.10C, increased tumorsphere formation ability was observed in
HeLa-Six1 as compared to HeLa-Ctrl. Taken together, our study demonstrates that Six1
overexpression increases the cancer stem cell-like cell population in HKc/DR and HeLa.

Figure 3.10 Six1 overexpression in HKc/DR and HeLa increases CSC properties. (A)
Analysis of CD24 and CD44 expression in Six1-overexpressing HKc/DR (DR-Six1)
or HKc/DR controls (DR-Ctrl) by flow cytometry. (B) Western blot of ALDH1 in
HKc/DR-Six1 and HKc/DR-Ctrl. β-actin was used as a loading control. (C)
Tumorsphere formation ability in HeLa-Ctrl and HeLa-Six1.
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Next, we determined if MAPK activation is associated with the increased CSC
population that was induced by Six1 overexpression. We examined the expression of
ALDH1 by Western Blotting in HKc/DR-Six1 treated with the ERK inhibitor U0126 (10
μM), the p38 inhibitor SB202190 (10 μM), the JNK inhibitor SP600125 (10 μM) or
DMSO for 48 h. The inhibition of p38 and JNK significant decreased ALDH1 protein
levels, indicating a decreased CSC population (Figure 3.11). Moreover, to test whether
TβRII-mediated signaling is necessary for Six1-induced CSC properties, we transfected
HKc/DR-Six1 with a dominant-negative TβRII plasmid (TβRIIDN). TβRIIDN lacks the
cytoplasmic tail and therefore cannot activate downstream signaling. As expected,
TβRIIDN decreased the expression of ALDH1 (Figure 3.11). Overall, our data indicate
that MAPK activation and TβRII signaling are critical for Six1-induced CSC properties.

Figure 3.11 TβRII-MAPK signaling is critical for
Six1-induced CSC properties. HKc/DR-Six1were
treated with the ERK inhibitor U0126 (10 μM),
the p38 inhibitor SB202190 (10 μM), the JNK
inhibitor SP600125 (10 μM) or DMSO for 48 h;
or HKc/DR-Six1were transfected with Ctrl or
TβRIIDN for 48 h. Western blot analysis for
ALDH1 and β-actin (loading control) was then
conducted.
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3.3 DISCUSSION
The Six1 homeoprotein is essential for the development of numerous organs, but
also contributes to cancer cell proliferation and survival. Six1 overexpression has been
found in various human cancers, and is associated with increased tumor progression and
metastasis, and poor prognosis (Christensen et al., 2008). Although overexpression of
Six1 had been observed in cervical cancer cell lines and tissues (Tan, Zhang, and Qian,
2011; Wan et al., 2008; Zheng et al., 2010), the role of Six1 in the progression of HPVmediated cancer was unknown. We demonstrate here that Six1 overexpression promotes
EMT at a late premalignant stage of HPV16-mediated transformation (HKc/DR). We
further show that increases in TβRII and TβRIII and activation of Smad-independent
TGF-β signaling are associated with Six1 overexpression and that p38 MAPK activation
is pivotal in Six1-induced EMT in HPV16-immortalized cells. Finally, we show that Six1
overexpression increases the CSC-like cell population in HKc/DR and results in
malignant conversion.
Previous studies showed that Six1 promotes cell proliferation and cell cycle
progression in breast cancer by up-regulating cyclin A1 (Coletta et al., 2004; Coletta et
al., 2008). Six1 promotes proliferation of pancreatic cancer cells by upregulation of
cyclin D1 expression (Li et al., 2013). However, in our study, we found decreased cell
growth in Six1-overexpressing HKc/DR as compared to controls in vitro. We did not
observe significant cell cycle changes in response to Six1 overexpression in HKc/DR.
The in vitro growth rate of Six1 overexpressing HeLa is comparable to the vector control,
but in vivo Six1 overexpressing HeLa form larger tumors. Clinically, Six1 overexpression
is associated with cervical cancer metastasis but not with tumor size (Zheng et al., 2010),
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indicating that Six1 is not critical for the regulation of tumor cell growth in cervical
cancer. Therefore, Six1-induced cell proliferation is context dependent, and cell cycleassociated growth promotion is not the main mechanism by which increased Six1
expression leads to enhanced aggressiveness and poor prognosis in cervical cancer.
Dysregulation of TGF-β signaling has been related to cervical cancer progression
and metastasis (Baritaki et al., 2007; Noordhuis et al., 2011). At early stages of
tumorigenesis, TGF-β acts as a potent tumor suppressor, strongly inhibiting the
proliferation of epithelial cells. However, at late stages of tumorigenesis, tumors become
resistant to growth inhibition by TGF-β and exploit TGF-β signaling to promote EMT,
thereby facilitating tumor metastasis and invasion (Meulmeester and Ten Dijke, 2011).
To date, several studies showed that imbalances in the activation status of canonical and
noncanonical TGF-β signaling may underlie the ability of TGF-β to induce EMT in
normal and malignant cells, and might be critical in the switch in TGF-β signaling from
tumor suppression to tumor promotion (Zhang, 2009). Therefore, we analyzed both
signaling pathways in response to Six1 overexpression in HKc/DR, and observed
significant MAPK activation, including ERK1/2, JNK and p38 MAPK. By using
inhibitors, we identified p38 MAPK as the primary mediator of Six1-induced EMT. The
activation of p38 MAPK by TGF-β, which induces EMT in normal and malignant cells,
requires the expression and activity of either β1 or β3 integrin, and the involvement of
TβRII (Bhowmick et al., 2001; Galliher and Schiemann, 2007). Based on our microarray
data, β1 integrin increased 2.3-fold and β3 integrin increased 3.3-fold in DR/Six1. Our
finding that the inhibition of p38 MAPK in HKc/DR-Six1 decreases the expression of
TβRII is consistent with the finding that TβRII is induced by a transcriptional mechanism
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involving p38 activation in breast cancer (Buck and Knabbe, 2006). The activation of
ERK1/2 and JNK may be due to increased expression of TβRII, or the dramatically
enhanced fibronectin expression, which activates ERK1/2 and JNK (Jiang, Jia, and
Cohen, 2002). Taken all together, these data suggest for the first time that Six1 augments
the p38-TβRII pathway, and thus promotes EMT during HPV16-mediated transformation
of human epithelial cells.
TGF-β-induced EMT is also thought to drive cells towards a more “cancer stem
cell-like” phenotype. Although very few studies demonstrate the role of TGF-β-induced
EMT on regulating CSCs in cervical cancer, it has been reported that induction of EMT
by TGF-β1 or its downstream targets, Snail or Twist, promoted the expression of cell
surface markers associated with CSCs (CD44+/CD24- phenotype) and tumorsphere
forming features in breast cancer (Mani et al., 2008). Interestingly, the specific activation
of TGF-β signaling in CD44+/CD24- breast cancer cells is due to the dramatically
increased expression of TβRII in these cells as compared to the corresponding CD44/CD24+ population (Shipitsin et al., 2007). Moreover, non-Smad TGF-β effectors β1 and
β3 integrin can induce CSC-like properties in breast cancer cells (Galliher and Schiemann,
2006; Galliher and Schiemann, 2007). We found that overexpression of Six1 promotes
EMT and enhances features of CSCs in HKc/DR, including promoting tumorigenesis in
vivo, augmenting the population of CD44+/CD24- and increasing expression of ALDH1.
Importantly, we found increased expression of TβRII, β1 integrin and β3 integrin, which
are consistent with TGF-β-induced CSCs in breast cancer. Furthermore, by using MAPK
inhibitors and expressing TβRIIDN, we determined the essential role of MAPK
activation and TβRII-mediated signaling in Six1-induced CSC phenotype. These findings
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strongly suggest that Six1 promotes tumor progression by inducing characteristics of
CSCs, and TGF-β-associated-EMT plays an important role in this process.
The precise role that the p38 MAPK pathway plays in tumor initiation and
progression is somewhat controversial. For example, p38 MAPK activation is implicated
in the suppression of tumorigenesis because it can inhibit cell growth by decreasing the
expression of cyclin D1 (Lavoie et al., 1996) However, p38 is essential for the expression
of vascular endothelial growth factor (VEGF), which promotes tumor angiogenesis
(Yoshino et al., 2006). P38 kinase is also important in promoting H-ras-specific cell
invasion and migration in human breast epithelial cells (Kim et al., 2003). The inhibition
of p38 kinase suppresses the proliferation of human ER-negative breast cancer cells
(Chen et al., 2009). In addition, it has been reported that an increased cancer stem cell
population found under hypoxia conditions and serum depletion is the result of activation
of p38 signaling (Lin et al., 2012). We determined that p38 MAPK plays an important
role in Six1-induced EMT and activation of noncanonical TGF-β signaling. To date, a
large number of small-molecule p38 MAPK inhibitors have been developed, some of
which are in clinical trials (Wagner and Nebreda, 2009). Based on our studies, p38
inhibitors might prove effective in the treatment of Six1 overexpressing malignancies.
In summary, we demonstrate that Six1 overexpression alters the TGF-β signaling
network, induces EMT, promotes malignant progression, and increases the CSC
population during HPV16-mediated transformation of HKc. We further establish a link
between Six1 overexpression and an activated p38-TβRII pathway, which contributes to
Six1-associated EMT and CSC characteristics. Recent studies have identified genes
related to organ specific metastasis, and suggested that tumor progression and metastasis
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is determined by the genetic characteristics of early-stage transformed cells (Bos et al.,
2009; Minn et al., 2007; Minn et al., 2005). Therefore, the pathways of Six1-induced
EMT and malignant conversion we uncovered in HKc/DR are likely to be relevant to
cancer progression and metastasis in general. This work provides a rationale for future
studies targeting the p38-TβRII pathway for the treatment of cancers overexpressing Six1.
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CHAPTER 4
SIX1 OVEREXPRESSION IN HPV16-IMMORTALIZED HUMAN KERATINOCYTES
PROMOTES DIFFERENTIATION RESISTANCE AND EMT

4.1 INTRODUCTION
Six1 is a member of the Six family of homeodomain transcription factors and is
essential for the development of numerous organs (Ikeda et al., 2010; Xu et al., 2003;
Zheng et al., 2003). Six1 overexpression has been found in various human cancers
including cervical cancer (Behbakht et al., 2007; Coletta et al., 2008; Ng et al., 2010;
Zheng et al., 2010). The overexpression of Six1 is associated with increased tumor
progression and metastasis, and decreased survival (Christensen et al., 2008). Six1 is
overexpressed in cervical cancer cell lines and cervical cancer tissues, and Six1
overexpression is correlated to increased tumor malignancy and lymph node metastasis
(Tan, Zhang, and Qian, 2011; Zheng et al., 2010). While our initial work determined that
the expression of SIX1 mRNA increased in HKc/DR compared to HKc/HPV16 (Wan et
al., 2008), we more recently reported that overexpression of Six1 in HKc/DR resulted in
increased cell motility and invasion by inducing epithelial-mesenchymal transition (EMT)
(Chapter 3) (Xu et al., 2014). Furthermore, induction of EMT by Six1 overexpression
was associated with activation of transforming growth factor beta receptor type 2
(TβRII)-p38 signaling (Chapter 3) (Xu et al., 2014). The fact that Six1 expression
increased during in vitro progression of HPV16-immortalized cells and Six1 was
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overexpressed in cervical cancer tissues (Wan et al., 2008; Zheng et al., 2010), strongly
suggests that Six1 might be involved in the cervical premalignant progression.
Therefore, in this study, we explored the role of Six1 during the early stages of
HPV16-mediated transformation by overexpressing Six1 in HKc/HPV16. We found that
Six1 overexpression in HKc/HPV16 increased cell proliferation and induced cell
migration and invasion by promoting EMT. Importantly, the overexpression of Six1 in
HKc/HPV16 resulted in resistance to serum and calcium-induced differentiation. Finally,
we found that activation of MAPK signaling is linked to resistance to calcium-induced
differentiation in HKc/HPV16 overexpressing Six1. Overall our results support the
conclusion that Six1 overexpression promotes differentiation resistance and EMT at early
stages of HPV16-mediated transformation of HKc.

4.2 RESULTS
4.2.1 SIX1 INCREASES PROLIFERATION, MIGRATION AND INVASION IN
HKC/HPV16
To further explore the function of Six1 in HKc/HPV16, we cloned a full-length
human Six1 cDNA into the expression plasmid pcDNA3.1 (pcDNA3.1-Six1).
HKc/HPV16-Six1 were established by stable transfection of HKc/HPV16 with
pcDNA3.1-Six1. HKc/HPV16-Ctrl were HKc/HPV16 transfected with the pcDNA3.1
expression plasmid alone. Western blots confirmed the overexpression of Six1 in
HKc/HPV16-Six1 (Figure 4.1A). HKc/HPV16-Six1 exhibited an elongated and
fibroblastic appearance (Figure 4.1B), and increased cell proliferation (Figure 4.1C)
compared to HKc/HPV16-Ctrl.
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Figure 4.1 Six1 overexpression in HKc/HPV16 changes cell morphology and
increases cell proliferation, invasion and migration. (A) HKc/HPV16 were stably
transfected with either pcDNA3.1 (Ctrl) or pcDNA3.1-Six1 (Six1). Six1 protein
levels in cell extracts were determined by western blotting. β-actin was used as a
loading control. (B) Cell morphology of HKc/HPV16-Ctrl and HKc/HPV16-Six1.
Images are shown at 100× magnification. (C) Proliferation in HKc/HPV16-Six1
(HKc-Six1) compared to HKc/HPV16-Ctrl (HKc-Ctrl) and HKc/HPV16 (HKc). Cell
numbers were determined by manually counting cells on the days indicated. (D)
Invasion (upper panels) and migration (lower panels) assays for HKc/HPV16-Ctrl
(HKc-Ctrl) and HKc/HPV16-Six1 (HKc-Six1). Cell invasion was determined by a
Matrigel invasion assay, and cell migration was determined by a transwell migration
assay. Images for the invasion assay are shown at 400× and those for the migration
assay at 100× magnification. Quantification of the invasion assay and the migration
assay are shown in the upper right and lower right panels, respectively. Each column
represents the mean of five different fields. Bars indicate SD, and ** and ***
indicate statistically significant p values < 0.01 and 0.001 respectively.
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Moreover, Six1 overexpression in HKc/HPV16 increased cell invasion by 4.5fold and cell migration approximately 4.2-fold (Figure 4.1D). These data demonstrate
that HKc/HPV16 overexpressing Six1 exhibited a more mesenchymal phenotype with
increased cell growth, migration and invasion compared to HKc/HPV16-Ctrl.

4.2.2 SIX1 PROMOTES EMT
Due to the changes in cell morphology, growth and invasion associated with Six1
overexpression, we next explored the expression of EMT related genes upon Six1
overexpression in HKc/HPV16. As shown in Figure 4.2A, the overexpression of Six1
induced an increased expression of mesenchymal markers and decreased expression of
epithelial markers. For example, the mRNA level of E-cadherin and occludin decreased
by about 81% and 76%, while mRNA levels of vimentin and snail increased by
approximately 2.0-, and 4.3-fold respectively in HKc/HPV16-Six1 when compared with
HKc/HPV16-Ctrl (Figure 4.2A). Moreover, we examined the protein levels of E-cadherin
and fibronectin by western blot analysis and immunofluorescence. The overexpression of
Six1 in HKc/HPV16 led to decreased E-cadherin and slightly increased fibronectin
(Figure 4.2B, C). We also investigated β-catenin, a key component of adherens junctions
in epithelial cells (Gumbiner, 2005), and we found that protein levels of β-catenin
decreased dramatically in Six1-overexpressing HKc/HPV16 (Figure 4.2B). Taken
together, our data show that Six1 overexpression promotes EMT in HKc/HPV16.
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Figure 4.2 Six1 overexpression induces EMT in HKc/HPV16. (A) Levels of mRNA
expression of E-cadherin, occludin, vimentin and snail were determined by Real-time
PCR in HKc/HPV16-Ctrl (HKc-Ctrl) and HKc/HPV16-Six1 (HKc-Six1). Data were
normalized to β-actin expression. Bars indicate SD, and *, ** and *** indicate
statistically significant p values < 0.05, 0.01 and 0.001 respectively. (B) Western blot
for Six1, E-cadherin, fibronectin and β-catenin in HKc/HPV16-Ctrl (Ctrl) and
HKc/HPV16-Six1 (Six1). β-actin was used as loading control. (C)
Immunofluorescent staining of E-cadherin (red) and fibronectin (red) in
HKc/HPV16-Ctrl and HKc/HPV16-Six1. Nuclei were stained with DAPI (blue).
Images are shown at 400× magnification.

4.2.3

THE

OVEREXPRESSION

OF

SIX1 IN

HKC/HPV16

RESULTS

IN

RESISTANCE TO SERUM AND CALCIUM-INDUCED DIFFERENTIATION
We determined protein levels of Six1 at the various stages of our in vitro model
for HPV16-mediated transformation. A large increase in Six1 expression was observed
in the final HKc/DR stage compared to the earlier HKc/HPV16 and HKc/GFI stages
(Figure 4.3). Unlike most other cell types, normal HKc and HKc/HPV16 can be
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propagated in serum-free media and under low Ca2+ conditions (i.e. 30 µM), and media
containing high-calcium (i.e.1 mM) or serum triggers the initiation of terminal squamous
differentiation (Boyce and Ham, 1983; Pirisi et al., 1988; Pirisi et al., 1987). The
hallmark of HKc/DR is resistance to serum and calcium-induced differentiation (Pirisi et
al., 1988). Therefore, we explored if the overexpression of Six1 is associated with
differentiation resistance. As shown in Figure 4.4A, HKc/HPV16-Ctrl stratified and
expressed keratin 10, a differentiation marker, after being treated with 1mM Ca2+ or 5%
FBS for 5 days. In contrast, HKc/HPV16-Six1 retained their proliferation, did not stratify
and did not express keratin 10 in response to Ca2+ or FBS. The cell morphology change
in HKc/HPV16-Ctrl could be observed as early as 24 h post 1mM Ca2+ or 5% FBS
treatment (Figure 4.4B). Upon being cultured in complete medium supplemented with 1
mM calcium chloride or 5% FBS, HKc/HPV16-Six1 showed mixed morphology of
enlarged cobblestone and spindle cells (Figure 4.4A, B). The enlarged/flat cobblestone
appearance is similar to the morphology of HKc/DR. Consistently, we found that keratin
10 protein levels dramatically increased at day 5 in HKc/HPV16-Ctrl, but not in
HKc/HPV16-Six1 (Figure 4.5A).
The E-cadherin-β-catenin complex at the plasma membrane plays a critical role
on cell differentiation in HKc and knocking-down E-cadherin or β-catenin expression
blocked calcium-induced keratinocyte differentiation (Xie and Bikle, 2007). We hence
examined E-cadherin by immunofluorescence and we found that both Six1overexpressing HKc/HPV16 and controls exhibited increased membrane-associated Ecadherin and intercellular junction formation when exposed in high Ca2+ medium
(Figure 4.4A). Then, we used western blotting to detect protein levels of total E-cadherin,
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fibronectin, as well as soluble (cytoplasmic) and insoluble (cytoskeletal-associated) Ecadherin after being exposed to 1mM Ca2+ for varying times (10 min to 5 days).

Figure 4.3 Western blot for Six1 in HKc/HPV16-low passage,
HKc/HPV16-high passage, HKc/GFI and HKc/DR that were
derived HKc/HPV16 lines (upper: D1, lower: D5). β-actin was used
as a loading control.
We found that total E-cadherin remained unchanged and the expression of
fibronectin decreased in both HKc/HPV16-Ctrl and Six1-overexpressing cells upon high
calcium

treatment

(Figure

4.5A).

Consistent

with

what

we

observed

by

immunofluorescence, HKc/HPV16-Six1 increased insoluble E-cadherin from 48 h after
high calcium treatment, indicating the formation of intercellular junctions (Figure 4.5B).
Phosphatidylinositol 3-kinase (PI3K)/AKT signaling can be activated by the E-cadherin
complex and promotes early keratinocyte differentiation (Xie and Bikle, 2007). However,
we did not observe any significant increase in phospho-PI3K or phospho-AKT in
response to high calcium treatment (Figure 4.6). Taken together, our data strongly
indicates that overexpression of Six1 in HKc/HPV16 results in resistance to Ca2+ or
serum-induced differentiation.
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Figure 4.4 Six1 overexpression in HKc/HPV16 results in resistance to
serum and calcium-induced differentiation. (A) HKc/HPV16-Ctrl and
HKc/HPV16-Six1 were cultured with either complete medium or complete
medium supplemented with 1 mM calcium chloride or 5% FBS for 5 days.
Cell morphology of HKc/HPV16-Ctrl and HKc/HPV16-Six1 under the
indicated treatment is shown in the first column (Phase).
Immunofluorescent staining of nuclei (blue), E-cadherin (red) and keratin
10 (green) in HKc/HPV16-Ctrl (upper panels) and HKc/HPV16-Six1
(lower panels) is shown in columns 2-4. (B) Cell morphology of
HKc/HPV16-Ctrl and HKc/HPV16-Six1 cultured in complete medium
(Ctrl) or complete medium containing high calcium (1 mM Ca2+) or serum
(FBS) for 24 h. Images are shown at 100× magnification.
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Figure 4.5 Six1 overexpression in HKc/HPV16 does not impact the
redistribution of adhesion junctions when cultured in high calcium media. (A)
Western blot of keratin 10, fibronectin and E-cadherin in whole cell lysate from
HKc/HPV16-Ctrl and HKc/HPV16-Six1 that were treated with 1 mM Ca2+ for
the indicated times. β-actin was used as a loading control. (B) The expression of
E-cadherin in soluble (cytosolic) and insoluble (cytoskeleton-associated)
fractions from HKc/HPV16-Ctrl and HKc/HPV16-Six1 that were treated with 1
mM Ca2+ for the indicated times. Fractions were analyzed by western blotting.

Figure 4.6 Western blot of p-PI3-kinase p85 (p-PI3K) and p-AKT in
HKc/HPV16-Ctrl and HKc/HPV16-Six1. Cells were cultured in 1 mM Ca2+
medium for the indicated times. β-actin was used as a loading control.
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4.2.4 SMAD-DEPENDENT TGF-Β SIGNALING IS DECREASED IN ASSOCIATION
WITH SIX1 OVEREXPRESSION
Next, we explored possible mechanisms of how Six1-overexpression in
HKc/HPV16 leads to resistance to calcium/serum-induced differentiation. Cell cycle exit
is one of the major processes involved in entering the terminally differentiated state
(Missero et al., 1995; Missero et al., 1996). TGF-β-Smad2/3 signaling induces cell cycle
withdrawal during keratinocyte terminal differentiation (Descargues et al., 2008), and
TGF-β1 enhances differentiation of HKc under high Ca2+ conditions (Matsumoto et al.,
1990). Moreover, TGF-β signaling is important in Six1-induced EMT (Micalizzi et al.,
2009; Micalizzi et al., 2010). Compared to HKc/HPV16-Ctrl, mRNA levels of TβRII and
TβRIII in HKc/HPV16-Six1 were increased 1.7-fold and 4.3-fold, respectively, while
TβRI mRNA was slightly decreased (Figure 4.7A). In addition, increases in the protein
levels of TβRII and TβRIII in HKc/HPV16-Six1 were detected by western blotting
(Figure 4.7B). We next investigated whether Six1-induced EMT and differentiation
resistance are linked to altered TGF-β-Smad2/3 signaling. We compared the both basal
and TGF-β stimulated activity of a Smad-responsive luciferase reporter construct
(p6SBE-Luc) in HKc/HPV16-Ctrl with HKc/HPV16-Six1. Six1 overexpression did not
change the basal activity of the Smad-dependent reporter construct (Figure 4.7C).
However, activation of Smad-dependent signaling in response to TGF-β1 treatment was
attenuated by ~ 45% in HKc/HPV16-Six1 as compared with HKc/HPV16-Ctrl (Figure
4.7D). These data suggest that Six1overexpression decreases activation of Smaddependent signaling in response to TGF-β1 treatment.
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Figure 4.7 Six1 overexpression in HKc/HPV16 alters TGF-β signaling. (A) Levels of
mRNA expression of TGF-β receptors TβRI, TβRII and TβRIII were determined by
Real time PCR in HKc/HPV16-Ctrl (HKc-Ctrl) and HKc/HPV16-Six1 (HKc-Six1).
Data were normalized to β-actin expression. (B) Western blot analysis of TβRII and
TβRIII in HKc/HPV16-Ctrl and HKc/HPV16-Six1. β-actin was used as a control for
equal protein loading. (C, D) HKc/HPV16-Ctrl (HKc-Ctrl) or HKc/HPV16-Six1
(HKc-Six1) were transfected with either p6SBE-luc or p6SME-luc. Twenty four h
after transfection, cells were treated with 40 pM TGF-β1 or vehicle for 24 h and then
luciferase activity determined. Values were normalized to Renilla luciferase. Bars
indicate SD, and ** and *** indicate statistically significant p values < 0.01 and <
0.001 respectively.

4.2.5 SIX1 ACTIVATES ERK AND P38 MAPK SIGNALING
The Mitogen-Activated Protein Kinases (MAPKs) are central players in
regulating keratinocyte differentiation (Eckert et al., 2002). MAPK signaling is one of the
non-Smad TGF-β pathways (Zhang, 2009) and we have previously found that activation
of MAPK is involved in Six1-induced EMT in HKc/DR (Xu et al., 2014). We compared
MAPK activity in HKc/HPV16-Ctrl and HKc/HPV16-Six1 by conducting Western blots

68

using phospho-specific p-ERK, p-p38 and p-JNK antibodies. As shown in Figure 4.8A,
phosphorylation of ERK and p38, but not JNK, was dramatically increased in response to
Six1 overexpression in HKc/HPV16. After treatment of HKc/HPV16-Ctrl with 1mM
Ca2+, ERK was phosphorylated within 1 h, and increased phosphorylation of p38 was
detected as soon as 10 min after Ca2+ treatment. In contrast, in HKc/HPV16-Six1, the
phosphorylation of ERK and p38 was not further increased but rather decreased within 1
h after high Ca2+ treatment (Figure 4.8B). Signal transducer and activator of transcription
3 (STAT3) also plays an important roles in differentiation, migration and apoptosis of
keratinocytes (Saeki et al., 2012). The phosphorylation of STAT3 increased in
HKc/HPV16-Six1 compared to HKc/HPV16-Ctrl (Figure 4.8B). However, there is no
STAT3 activation in HKc/HPV16-Ctrl following high Ca2+ treatment

and the

phosphorylation of STAT3 decreased in HKc/HPV16-Six1 following the addition of
high Ca2+ medium (Figure 4.8B).

Figure 4.8 Six1 overexpression in HKc/HPV16 modulates MAPK signaling. (A)
Protein levels of p-ERK, ERK, p-p38, p38, p-JNK and JNK were determined by
western blotting of cell lysates prepared from HKc/HPV16-Ctrl and HKc/HPV16Six1. (B) Western blot of p-ERK, p-p38, p-JNK and p-STAT3 in HKc/HPV16-Ctrl
and HKc/HPV16-Six1 that were cultured in 1 mM Ca2+ medium for the indicated
times. β-actin was used as control for protein equal loading.
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4.2.6 THE ACTIVATION OF ERK AND P38 MAPK IS CRITICAL FOR SIX1INDUCED EMT
We treated HKc/HPV16-Six1 with MAPK inhibitors to explore the role of MAPK
activation in Six1 induction of EMT. Treatment of HKc/HPV16-Six1 with the p-ERK
inhibitor U0126 and p38 inhibitor SB202190 almost completely blocked the expression
of fibronectin (Figure 4.9). HKc/HPV16-Six1 treated with SB202190, but not U0126 or
SP600125 increased E-cadherin protein level (Figure 4.9). Moreover, HKc/HPV16-Six1
treated with SB202190 and U0126, but not SP600125, lost some of their fibroblastic
appearance (Figure 4.10A). Lastly, similar to what we observed in HKc/DR, Six1overexpressing HKc/HPV16 treated with SB202190 exhibited a decreased ability to
invade through Matrigel (Figure 4.10B). Given the minimal changes in JNK activity in
response to Six1-overexpression in HKc/HPV16, we conclude that ERK and p38 MAPK
signaling plays an important role in promoting EMT in Six1 overexpressing HKc/HPV16.

Figure 4.9 Western blot analysis for E-cadherin, fibronectin and β-actin
(loading control). HKc/HPV16-Six1 were treated for 48 h with the ERK
inhibitor U0126 (10 μM), the p38 inhibitor SB202190 (10 μM), the JNK
inhibitor SP600125 (10 μM) or DMSO.
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Figure 4.10 Inhibition of ERK and p38 reverses Six1-meditated EMT. (A) phasecontrast photographs of HKc/HPV16-Six1 (HKc-Six1) treated with the ERK
inhibitor U0126 (10 μM), the p38 inhibitor SB202190 (10 μM), the JNK inhibitor
SP600125 (10 uM) or DMSO for 48 h. Images are shown at 100× magnification.
(B) Invasion assays for DR-Six1 treated with DMSO or SB202190 (10 μM for 24
h). Cell invasion was determined by a Matrigel invasion assay. The number of
invading cells was quantified after crystal violet staining. Images are shown at
100× magnification. Crystal violet was extracted with ethanol and the absorbance
determined in a spectrophotometer. Quantification of the invasion assay is
presented in the bar graph next to the photographs. Each column represents the
mean of three repeats.
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4.3 DISCUSSION
Accumulating evidence has determined that inappropriate expression of
homeobox genes in cancer contributes to tumorigenesis and tumor progression (AbateShen, 2002). The Six1 homeoprotein is essential for embryonic development, and also
contributes to cancer cell proliferation and survival. The overexpression of Six1 has been
found in various cancers, and is associated with increased tumor progression and
metastasis, and decreased survival (Christensen et al., 2008). Our previous work
determined that SIX1 mRNA expression increased during in vitro progression of HPV16immortalized HKc and that Six1 protein was overexpressed in cervical cancer tissues,
which strongly suggests that Six1 might play an important role in the progression of
premalignant cervical lesions initiated by HPV infection (Wan et al., 2008). In the current
study, we focused on the role of Six1 at early stages of HPV16-mediated transformation.
We demonstrated that that Six1 overexpression promotes EMT and resistance to serum
and high calcium-induced differentiation in HKc/HPV16. We further showed decreased
TGF-β-Smad2/3 signaling, alterations in the expression of TGF-β receptors and the
activation of ERK and p38 MAPK in association with Six1 overexpression in
HKc/HPV16.
Immortality, decreased requirements for growth factors and lack of response to
differentiation stimuli are characteristics of a transformed phenotype. In our in vitro
model system of HPV16-mediated transformation, HKc/HPV16 immortalized cells
resistant to calcium and serum-induced differentiation (HKc/DR) were selected from
growth factor independent HKc/HPV16 (HKc/GFI). (Pirisi et al., 1988). Here we
demonstrate that Six1 overexpression in HKc/HPV16 induces resistance to calcium and
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serum -induced differentiation, suggesting that Six1 can promote progression during the
early stages of HPV16-mediated transformation.
TGF-β signaling plays a dual role in tumor progression and dysregulation of
TGF-β signaling is believed to be associated with progression of premalignant cervical
lesions to cervical cancer (Baritaki et al., 2007; Noordhuis et al., 2011). TGF-β acts as a
potent tumor suppressor since it strongly inhibits the proliferation of normal and early
neoplastic cells. However, at late stages of tumorigenesis, tumors become resistant to
TGF-β mediated growth inhibition and exploit TGF-β signaling to facilitate tumor
metastasis and invasion (Meulmeester and Ten Dijke, 2011). In our in vitro model system,
HKc/DR exhibit decreased expression of TβRI, which results in resistance to the
antiproliferative effects of TGF-β (Mi et al., 2000). In this study, we found that Six1
overexpression dramatically reduced Smad-dependent signaling in response to TGF-β1.
Decreased Smad-dependent signaling may contribute to the enhanced proliferation we
observed in HKc/HPV16-Six1. On the contrary, we previously showed that Six1
overexpression decreased cell growth in HKc/DR (Xu et al., 2014). The different growth
response to Six1 overexpression in HKc/HPV16 and HKc/DR may be explained by the
different expression of TGF-β receptors and TGF-β signaling. Moreover, TGF-β is one of
the primary serum factors responsible for inducing keratinocytes to undergo terminal
differentiation (Bertolero et al., 1986). Thus, the decreased Smad signaling found in
HKc/HPV16-Six1 likely plays a role in the resistance of these cells to serum-induced
differentiation.
EMT allows immotile and polarized epithelial cells to acquire a motile, apolar and
fibroblastoid phenotype, and has been considered being a critical step in mediating tumor
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progression, metastasis as well as cancer stem cell properties (Christiansen and
Rajasekaran, 2006; Mani et al., 2008). TGF-β can induce EMT through Smad-dependent
and non-Smad signaling (Lamouille, Xu, and Derynck, 2014; Zhang, 2009). In our study,
we found increased expression of TβRII and TβRIII in Six1-overexpressing HKc/HPV16,
but we did not find any increase in Smad-dependent signaling. After examining typical
non-Smad TGF-β pathways, we showed a significant activation of ERK and p38 MAPK
in response to Six1 overexpression in HKc/HPV16. Inhibition of ERK and p38 MAPK
activity in HKc/HPV16-Six1 significantly decreases the expression of fibronectin (a
mesenchymal marker) and the cells also lose their fibroblastic appearance. These findings
are consistent with our observation in HKc/DR, in which Six1 overexpression activates
MAPK and MAPK activation is critical for Six1-induced EMT (Xu et al., 2014). Taken
together, our data suggest that the MAPK activation is responsible for Six1-induced EMT
in both HKc/HPV16 and HKc/DR.
Besides the association with EMT, MAPKs are vital for the regulation of
keratinocyte differentiation (Eckert et al., 2002). For example: p38 MAPK functions to
promote HKc differentiation by regulating the expression of involucrin, a marker of
keratinocyte differentiation (Dashti, Efimova, and Eckert, 2001). High calcium induces a
transient, peak-like activation of ERK in HKc, and calcium-induced differentiation can
be blocked by MEK inhibition, which suggests an important role of the MEK/ERK
pathway in the early stages of keratinocyte differentiation (Schmidt et al., 2000). In our
study, we showed that the level of phosphorylation of ERK and p38 increased in
HKc/HPV16-Ctrl upon high calcium treatment. In contrast, the activity of ERK and p38
decreased in HKc/HPV16-Six1 following treatment with high calcium. STAT3 also has
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been known to play an important role in keratinocyte differentiation. Constitutive
activation of Stat3 in mouse epidermis results in partial loss of the keratinocyte
differentiation markers K10 and filaggrin and enhances malignant progression (Chan et
al., 2008). STAT3 knock-down induces immature terminal differentiation of HKc (Saeki
et al., 2012). Our study showed a significant activation of STAT3 in Six1-overexpressing
HKc/HPV16. STAT3 overexpression in HKc/HPV16-Six1 may in fact retard
differentiation even though these cells express high levels of p-ERK and p-p38.
In summary, Six1 overexpression in HKc/HPV16 induces cell proliferation,
invasion, migration, and EMT and induces resistance to calcium/serum-induced
differentiation. Although TβRII and TβRIII levels are increased in HKc/HPV16-Six1,
Smad-dependent TGF-β signaling is reduced, while MAPK is activated. Activation of
MAPK in HKc/HPV16 overexpressing Six1 is associated with resistance to calciuminduced terminal differentiation, although the precise mechanism remains to be
determined.
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CHAPTER 5
SIX1 PROMOTES COLORECTAL CANCER GROWTH AND METASTASIS BY
STIMULATING ANGIOGENESIS AND RECRUITING TUMOR-ASSOCIATED
MACROPHAGES

5.1 INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy and the third
leading cause of cancer-related death in men and women in the United States. According
to statistics from the American Cancer Society, in 2014 an estimated 71,830 men and
65,000 women will be diagnosed with colorectal cancer; and 26,270 men and 24,040
women will die of the disease (Siegel, Desantis, and Jemal, 2014).
The Six1 homeoprotein, a member of the Six family of homeodomain
transcription factors, is essential for the development of numerous organs (Ikeda et al.,
2010; Xu et al., 2003; Zheng et al., 2003). Six1 overexpression has been found in various
human cancers and is associated with increased tumor progression and metastasis, and
decreased survival (Christensen et al., 2008). Recently, Six1 overexpression has been
found to be significantly associated with poorer overall survival in advanced-stage CRC
(stages III and IV), where cancer metastasis to regional lymph nodes or distant organs has
occurred (Wong et al., 2014). However, there is no statistically significant correlation
between the extent of Six1 expression and prognosis in patients with CRC at all stages
(Ono et al., 2012). Studies using RNA interference have demonstrated that inhibition of
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Six1 expression suppresses CRC cell growth and invasion (Li et al., 2014). Together
these findings suggest that Six1 overexpression may promote CRC progression and
metastasis. Therefore, in this study, we investigated the role of Six1 on tumor progression
and metastasis in mouse and human CRC cell lines. We find that overexpression of Six1
dramatically promotes CRC tumor growth and metastasis in vivo, increases features of
cancer stem cells (CSCs), and stimulates angiogenesis by up-regulating the expression of
vascular endothelial growth factor (VEGF). Furthermore, we determined that Six1
overexpression results in the recruitment of tumor-associated macrophages (TAM) by
increasing the expression of macrophage-specific colony-stimulating factor (CSF-1),
chemokine (C-C motif) ligand 2/5 (CCL2/5) and VEGF, which further facilitates CRC
tumor growth and metastasis.

5.2 RESULTS
5.2.1 THE OVEREXPRESSION OF SIX1 ENHANCES CRC TUMOR GROWTH AND
METASTASIS
To explore the association between Six1 overexpression and CRC development,
we examined the expression of Six1 mRNA in the intestines from C57BL/6 mice,
intestines from C57BL/6-APCMin/+ mice and tumors from C57BL/6-APCMin/+ mice. We
observed increased expression of Six1 in the intestines from C57BL/6-APCMin/+ mice
compared to that from wild type C57BL/6 mice, and the mRNA level of Six1 was
dramatically increased in tumors from C57BL/6-APCMin/+ mice Figure 5.1). Next, we
chose as a model system the tumorigenic but poorly metastatic mouse colon cancer cell
line MC38 to investigate CRC progression in response to Six1 overexpression (Smith et
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al., 2010). A surgical orthotopic homograft mouse model was used to explore the role of
Six1 on tumor behavior in vivo by injecting MC38 vector control cells (MC38-Ctrl) and
MC38 cells overexpressing Six1 (two independently-derived clones, MC38-Six1-1 and
MC38-Six1-2) into the cecal subserosa of syngeneic C57BL/6 mice. As shown in Figure
5.2A and 5.2B, Six1-overexpressing MC38 cells formed primary tumors in 75% of
implanted mice (15 out of 20), and the average tumor weight was ~420 mg. In contrast,
MC38-Ctrl cells formed tumors in only 25% of the injected mice (5 out of 20), and the
average tumor weight was ~132 mg. Thus, Six1-overexpression in MC38 cells
significantly increased both tumor incidence and growth in vivo compared to MC38-Ctrl.

Figure 5.1 mRNA levels of Six1 increases during APCMin/+
mice tumorigenesis. The expression of Six1 mRNA was
detected by real time PCR in intestines from C57BL/6 mice,
intestines from C57BL/6-APCMin/+ mice and tumors from
C57BL/6-APCMin/+ mice.
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Figure 5.2 Six1 overexpression increases CRC tumor growth and metastasis in vivo.
(A) Six1-overexpressing MC38 (MC38-Six1) or controls (MC38-Ctrl) were
orthotopically injected into the cecum subserosa of C57BL/6 mice and 6 weeks
later the mice were sacrificed. Left panels: tumors from MC38-Ctrl. Right panels:
tumors from MC38-Six1. (B) The weight of tumors and tumor incidence in mice
injected in the cecum with MC38-Ctrl or isolates of MC38-Six1 cells. (C) Upper
panel: livers and spleens from Six1-overexpressing MC38 (MC38-Six1) tumorbearing mice. Lower panel: livers and spleens from MC38-Ctrl tumor-bearing mice.
(D) The weight of livers (left panel) and spleens (right panel) from Six1overexpressing MC38 (MC38-Six1) or MC38-Ctrl tumor-bearing mice.
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The liver is one of the most common sites of metastatic spread of CRC, and
autopsies have found that up to 70% of colon cancer patients had liver metastasis at the
time of death (Schima et al., 2005). To determine whether Six1 is involved in CRC
metastasis, we used a splenic injection model to compare liver metastasis in MC38-Six1
to MC38-Ctrl. We found that mice injected with MC38-Six1 cells formed larger tumor
burdens in the spleen and developed more metastases in the liver compared to those
injected with MC38-Ctrl cells. However, interestingly the size of primary tumors in the
spleen did not correlate to the extent of metastasis in the liver in either the MC38-Ctrl or
MC38-Six1 groups (Figure 5.2C). We used liver weight as an indicator for the degree of
liver metastases, and spleen weight as an indicator for the size of tumor in the spleen. As
shown in Figure 5.2D, mice injected with Six1-overexpressing MC38 cells showed
significantly increased spleen and liver weight as compared to those injected with MC38Ctrl cells, suggesting that Six1 overexpression increased primary tumor growth and
metastatic spread. Taken together, our results suggest that the overexpression of Six1
promoted CRC growth and metastasis.

5.2.2 SIX1 INCREASES FEATURES OF CANCER STEM CELLS (CSCS) IN
COLORECTAL CANCER
We next sought to explore how Six1 overexpression promotes CRC growth and
metastatic spread. We analyzed several properties of tumors in the cecum arising from
mice injected with either MC38-Ctrl or MC38-Six1 cells. Since the increased tumor size
found in MC38-Six1 cells could be the result of increased proliferation or decreased
apoptosis, we used immunohistochemistry to compare the cell proliferation marker Ki67
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and the apoptosis marker cleaved caspase-3 in MC38-Ctrl and MC38-Six1 tumors.
Tumors overexpressing Six1 (MC38-Six1) showed increased levels of Ki67 positive cells
but we found no marked difference in the percentage of cleaved caspase-3 positive cells
compared to the controls (MC38-Ctrl) (Figure 5.3A), suggesting the effect of Six1 on
tumor growth is associated with increased cell proliferation rather than alterations in the
rates of apoptosis. However, when we compare cell proliferation in vitro, Six1
overexpression slightly suppressed cell growth in MC38 (Figure 5.3B) rather than
increasing cell proliferation as we found in the in vivo cecal model studies. Moreover, we
analyzed by Western blot the levels of several proteins involved in cell proliferation,
such as c-Myc, PCNA, cyclin D1, and cyclin E, and found that none of them were upregulated in Six1-overexpressing MC38 cells compared to the control cells (Figure 5.3C),
indicating again that Six1 overexpression did not increase cell proliferation in vitro as it
did in vivo. This observation, coupled with our previous finding that Six1 is associated
with an increased CSCs population during HPV16-mediated transformation (Xu et al.,
2014), led us to examine whether Six1 could enhance CSCs characteristics in MC38,
thereby promoting CRC tumor progression. To this end, we determined the expression of
ALDH1 in MC38-Ctrl and MC38-Six1 in tumors and in lysates from cultured MC38
cells. We found that the protein level of ALDH1 increased dramatically in tumors derived
from MC38 cells overexpressing Six1 and in cultured MC38-Six1 cells compared to
MC38-Ctrl (Figure 5.3A, C). Cell surface antigens CD44+ and CD166+ have been
considered as CRC CSCs markers (Dalerba et al., 2007; Levin et al., 2010). We thus
measured CD44+/CD166+ populations in MC38-Ctrl and MC38-Six1 by flow cytometry.
Six1-overexpressing MC38 cells had a markedly increased CD44+/CD166+ population
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(41.3% in MC38-Six1 versus 3.8% in MC38-Ctrl) (Figure 5.3D). Furthermore, we
examined tumorsphere formation ability of MC38-Ctrl and MC38-Six1. As shown in
Figure 5.3E, increased number of tumorspheres was observed in MC38-Six1 as compared
to MC38-Ctrl. In all, our findings demonstrate that Six1 overexpression increases the
cancer stem cell-like cell population in CRC cells.

Figure 5.3 Six1 overexpression in MC38 cells increases CSC characteristics. (A) The
expression of Ki67, cleaved caspase-3 and ALDH1 in tumors arising from mice
injected in the cecum with MC38-Ctrl and MC38-Six1 as detected by
immunohistochemistry. (X400) (B) Cell proliferation was determined by directly
counting cells at the days indicated in MC38-Six1 and MC38-Ctrl. (C) Western blots
for Six1, c-Myc, PCNA, cyclin D1, cyclin E and ALDH1 in MC38-Ctrl and two
isolates of MC38 overexpressing Six-1 (MC38-Six1). β-actin was used as a loading
control. (D) Analysis by flow cytometry of CD166 and CD44 expression in MC38
overexpressing Six1 (MC38-Six1) or MC38 controls (MC38-Ctrl). (E) Tumorsphere
formation ability in MC38-Ctrl and MC38-Six1. Bars indicate SD and * indicates p
values < 0.05.
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5.2.3 SIX1 OVEREXPRESSION STIMULATES ANGIOGENESIS IN CRC TUMORS
Histopathological analysis showed a hyper-cellular solid carcinoma with high
grade atypia and frequent mitosis in both Six1-overexpressing and control tumors (Figure
5.4A). Interestingly, we noted that in Six1-overexpressing tumors (MC38-Six1), there
were more vessels, especially blood vessels, located within the tumor mass as compared
to control tumors (MC38-Ctrl) (Figure 5.4A). CD31 and α-SMA staining was used to
demonstrate the presence of vascular endothelial cells and pericytes in blood vessels.
Tumors arising form MC38-Six1 cells had greater numbers of CD31 and α-SMA positive
cells compared to that from MC38-Ctrl cells (Figure 5.4A), indicating that Six1
overexpression promotes tumor angiogenesis. In addition, we analyzed the levels of
proteins that are related to tumor angiogenesis and metastasis in sera from MC38-Six1
and MC38-Ctrl tumor-bearing mice. We found that the protein levels of VEGF, MMP9
and lysyl oxidase (LOX) increased, and that of MMP2 remained the same in sera of
MC38-Six1 tumor-bearing mice as compared to MC38-Ctrl mice (Figure 5.4B).
Furthermore, immunohistochemical analyses demonstrated increased protein levels of
MMP9, VEGF and LOX in MC38-Six1 compared to MC38-Ctrl tumors (Figure 5.4C).
These results support that the increased accumulation of MMP9, VEGF and LOX we
observed in the serum of tumor-bearing mice was due at least in part to the increased
expression of these proteins in MC38-Six1 tumors rather than the larger size of the
MC38-Six1 tumors compared to MC38-Ctrl. Taken together these data indicate that Six1
overexpression in CRC tumors stimulates angiogenesis and metastasis by increasing the
expression of VEGF, LOX and MMP9.
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Figure 5.4 Six1 overexpression promotes angiogenesis. (A) Upper panels: H&E
staining of primary tumors formed in the cecum of mice from MC38-Ctrl and
MC38-Six1. Lower panels: immunofluorescent staining of CD31 (red) and α-SMA
(red) merged with nuclei (blue) in MC38-Ctrl and MC38-Six1 tumors. Images are
shown at the indicated magnification. (B) Western blots for VEGF, MMP2,
MMP9 and LOX in sera from Six1-overexpressing MC38 tumor-bearing mice
(MC38-Six1) and control mice (MC38-Ctrl). Albumin was used as a loading
control. (C) The expression of MMP9, VEGF and LOX in MC38-Six1 and MC38Ctrl tumors as assessed by immunohistochemistry (X400).
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5.2.4 SIX1 OVEREXPRESSION PROMOTES MC38 CELL MIGRATION AND
INVASION IN VITRO.
Since Six1 overexpression in MC38 cells enhanced tumor progression and
metastasis in vivo, we sought to identify changes in cell behavior associated with Six1
overexpression. In a wound healing assay, MC38 overexpressing Six1 (MC38-Six1)
exhibited enhanced cell migration compared to MC38 control cells (MC38-Ctrl) (Figure
5.5A).

Figure 5.5 Six1 overexpression in MC38 increases migration and invasion in vitro.
(A) Cell migration was determined by a wound healing assay. Microscopic images
are at 100X magnification. The area of the wound is quantified to determine the
extent of wound repair. (B) Cell invasion was determined by a Matrigel invasion
assay. Images are shown at 400X magnification. The number of invading cells was
quantified after crystal violet staining. Each column represents the mean of five
different fields. Bars indicate SD and ** indicates p values < 0.01.
MC38-Six1 also showed ~3.2-fold increase in cell invasion through Matrigel
compared to MC38-Ctrl (Figure 5.5B). Consistent with what we found in tumor tissue
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and in MC38-Six1 tumor-bearing mice, MC38-Six1 cells in vitro displayed increased
protein levels of MMP9 and VEGF, but not MMP2 compared to MC38-Ctrl cells (Figure
5.6A). These results show that Six1 increases MC38 cell migration and invasion in vitro.

5.2.5 SIX1 OVEREXPRESSION ACTIVATES ERK AND P38 MAPK IN MOUSE
AND HUMAN CRC CANCER CELL LINES
Epithelial-mesenchymal transition (EMT) enables polarized epithelial cells to
acquire enhanced migratory capacity and invasiveness, and has been considered as a
critical step in mediating tumor progression, metastasis as well as stem cell properties
(Christiansen and Rajasekaran, 2006; Mani et al., 2008). Six1-induced EMT has been
elucidated in various cancers (Micalizzi et al., 2009; Ono et al., 2012; Xu et al., 2014).
We compared the expression of typical EMT-related genes in MC38-Six1 to MC38-Ctrl
cells by Western blotting. Surprisingly, we only observed a small decrease in E-cadherin
and no marked change in vimentin or β-catenin (Figure 5.6A) levels; suggesting EMT is
not an important cellular response to Six1 overexpression in MC38. In HPV16
immortalized human keratinocytes, we previously reported that Six1 overexpression
leads to activation of MAPK signaling, especially phosphorylation of ERK and p38
MAPK (Xu et al., 2014). Similarly, the phosphorylation of p38 and ERK, but not JNK,
increased considerably in Six1-overexpressing MC38 compared to MC38-Ctrl (Figure
5.6A).
We also compared some of the molecular changes associated with Six1
overexpression in mouse MC38 to Six1 overexpressing human CRC cell lines HT29 and
SW480. Protein levels of PCNA and cleaved caspase-3 remained the same in Six1overexpressing and control cells, indicating that Six1 overexpression had no major
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impact on human CRC cell proliferation and apoptosis in vitro (Figure 5.6B). Six1
overexpression significantly decreased the expression of E-cadherin in SW480, and only
slightly decreased E-cadherin in HT29. Interestingly, ERK and p38 MAPK
phosphorylation was dramatically increased in Six1-overexpressing SW480 and HT29
compared to their corresponding controls (Figure 5.6B). Combining the results from
MC38 and human CRC cells, we conclude that Six1 overexpression does not promote
EMT or affect CRC cell growth and apoptosis in vitro but Six1 overexpression does
activate the ERK and p38 MAPK pathway.

Figure 5.6 The overexpression of Six1 activates ERK and p38 MAPK in human
and mouse CRC cell lines. (A) Western blots for MMP2, MMP9, VEGF, Ecadherin, vimentin, β-catenin, p-p38, p-JNK and p-ERK in two different isolates of
MC38 overexpressing Six1 (MC38-Six1) and controls (MC38-Ctrl). (B) Western
blots for Six1, PCNA, cleaved caspase-3, E-cadherin, ALDH1, p-ERK and p-p38
in two different isolates of Six1-overexpressing HT29 (HT29-Six1) and SW480
(SW480-Six1) and corresponding controls (HT29-Ctrl and SW480-Ctrl). β-actin
was used as a loading control.
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5.2.6

THE

OVEREXPRESSION

OF

SIX1

IN

MC38

ENHANCES

THE

RECRUITMENT OF TUMOR-ASSOCIATED MACROPHAGES (TAM)
In contrast to the results obtained from the orthotopic CRC model, in which
MC38-Six1 tumors were significantly larger than MC38-Ctrl tumors in the cecum, in the
subcutaneous injection model, Six1-overexpressing MC38 cells formed larger tumors in
the flanks of C57BL/6 mice in some animals, but the increase in tumor weight was not
statistically significant (Figure 5.7A).
This observation, along with some of our results with MC38 cells in culture,
suggested that the tumor microenvironment is critical for Six1-induced tumor progression.
The tumor microenvironment, also referred to as

the tumor-associated stroma, is

composed of non-neoplastic cells such as fibroblasts, infiltrating immune cells,
endothelial cells and structural components (Hanahan and Coussens, 2012). In CRC,
tumor-infiltrating immune cells, cytokines and other immune mediators are involved in
almost all steps of colon tumorigenesis, including initiation, promotion, progression and
metastasis (Terzic et al., 2010). For this reason, we investigated whether Six1
overexpression was associated with systemic inflammation, by examining the peripheral
white blood cell (WBC) count. As shown in Figure 5.7B, the peripheral WBC count from
MC38-Six1 and MC38-Ctrl tumor-bearing mice both fall within the normal range (gray
zone), and there was no significant difference between them. We then analyzed the
percentage of lymphocytes, monocytes and neutrophils in peripheral WBC, and none of
them showed significant differences in C57BL/6 mice bearing MC38-Six1 tumors in
their cecum compare to control mice (Figure 5.7C). We also examined the protein levels
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of three proinflammatory cytokines (IL-1β, IL-6 and TNF-α) in the sera of these mice,
and found no consistent differences (Figure 5.7D).

Figure 5.7 Six1 overexpression does not induce systemic inflammation. (A) Six1overexpressing MC38 (MC38-Six1) or controls (MC38-Ctrl) were injected into
the flank of C57BL/6 mice and the mice sacrificed 6 weeks later (n = 9-10). The
weight of tumors formed from MC38-Ctrl and MC38-Six1 is shown. (B)
Peripheral white blood cell (WBC) count from MC38-Six1 and MC38-Ctrl tumorbearing mice (cecal implantation). (C) Percentage of lymphocytes, monocytes and
neutrophils in peripheral WBC from MC38-Six1 and MC38-Ctrl tumor-bearing
mice (cecal implantation). (D) The protein levels of IL-1β, IL-6 and TNF-α in sera
from Six1-overexpressing MC38 tumor-bearing mice (MC38-Six1) and control
mice (MC38-Ctrl) (cecal implantation).
Like other solid tumors, CRC tumors are infiltrated by various types of immune
cells, including T cells, neutrophils, mast cells, natural killer (NK) cells and TAM (Terzic
et al., 2010). To identify the altered population of immune cells, we performed flow
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cytometry analyses to detect major immune cell types, using a combination of
immunostaining and found low numbers or small changes in B cells, T cells, mast cells or
natural killer cells (data not shown) A significant increase in the CD11b+/F4/80+ cell
population was observed in MC38-Six1 tumors compared to MC38-Ctrl (28.8% ± 5 in
MC38-Six1 versus 11.8% ± 1.9 in MC38-Ctrl), indicating Six1 overexpression in MC38
increased macrophage infiltration (Figure 5.8A). We also observed a reduction in
CD11b+/Gr1+ population (a marker for neutrophils) in some Six1-overexpressing tumors
when compared with control tumors, but the reduction was not statistically significant
(Figure 5.8A).
We

also

detected

the

F4/80

positive

cells

in

tumor

samples

by

immunohistochemistry. Large clusters of F4/80 positive macrophages were observed in
Six1-overexpressing tumors (MC38-Six1) but infrequently found in control tumors
(MC38-Ctrl) (Figure 5.8B). Furthermore, we used immunofluorescence to visualize
VEGF and F4/80 positive cells in MC38-Six1 tumor sections. Consistent with what we
showed in Figure 5.4C, in which some small stromal cells were strongly positive for
VEGF, we observed colocalization of VEGF-positive cells and F4/80 positive cells
(Figure 5.9), suggesting TAM expressed VEGF to further facilitate tumor angiogenesis.
These results suggest that Six1 overexpression in MC38 recruits TAM and further
promotes tumor angiogenesis, and this increase in the TAM population in the tumor is
most likely due to the recruitment of TAM by tumor cells, not due to the systemic
inflammation.
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Figure 5.8 MC38 cells overexpressing Six-1 recruit macrophages to tumors. (A) Left
panels: Flow cytometric analysis of the expression of CD11b, F4/80 and Gr1 in
Six1-overexpressing MC38 tumors (MC38-Six1) and control tumors (MC38-Ctrl).
Right panels: the percentage of total cells positive for either CD11b+F4/80+ (marker
for macrophages) or CD11b+Gr1+ (marker for neutrophils) cells. Results are
representative of seven independent experiments. (B) Immunohistochemical analysis
of the expression of F4/80 in MC38-Ctrl and MC38-Six1 derived tumors (X400).

5.2.7 SIX1 INCREASES THE EXPRESSION OF CSF-1 AND CCL2/5, AND
THEREBY AUGMENTS THE RECRUITMENT OF TAM
It is now generally accepted that TAM, through the secretion of cytokines,
chemokines, and growth factors, exert pro-tumor functions by promoting tissue
remodeling and angiogenesis rather than cytotoxic activity (Qian and Pollard, 2010).
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TAM can be recruited to CRC tumor sites by several molecules, including CCL2 and
CCL5, VEGF and CSF-1 (Erreni, Mantovani, and Allavena, 2011). We determined that
the mRNA expression of CSF-1, CCL2, CCL5, and VEGF was increased in MC38
overexpressing Six1 compared to MC38-Ctrl (Figure 5.10A).

Figure 5.9 Immunofluorescent staining of VEGF (green), F4/80 (red) and merged
with nuclei (blue) in MC38-Six1 derived tumors. In the merged image the yellow
color indicates colocalization of VEGF and F4/80. Images are shown at 400×
magnification.

Figure 5.10 Six1 overexpression in MC38 increases the expression of molecules that
induce chemotaxis of TAM. (A) mRNA expression of CSF-1, CCL2, CCL5 and
VEGF were detected by real time PCR in MC38-Ctrl and MC38-Six1. (B) mRNA
levels of CSF-2, CSF-3 and CXCL1 was determined by real time PCR in MC38-Ctrl
and MC38-Six1. (C) mRNA expression of HIF-1α and HIF-1β was determined by
real time PCR in MC38-Ctrl and MC38-Six1. Real time PCR data were normalized
to β-actin expression. Bars indicate SD, and ** and *** indicate p values < 0.01 and
0.001 respectively. (D) Protein levels of HIF-1α were examined by
immunohistochemistry (X400) in MC38-Ctrl and MC38-Six1 derived tumors.
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We also explored mRNA expression of cytokines related to the recruitment of
neutrophils to tumors, including granulocyte-macrophage colony-stimulating factor-2
(CSF-2), granulocyte colony-stimulating factor-3 (CSF-3) and CXCL1. We found
decreased expression of CSF-2 and CSF-3 in MC38-Six1, and increased expression of
CXCL1 (Figure 5.10B). This may help explain the wide variation in the proportion of
neutrophils in tumors in the same group, and our finding that there was no difference in
the neutrophils in tumors overexpressing Six1 and controls (Figure 5.8A). Since TAM
can be recruited into tumors and accumulate in areas of hypoxia (Lewis and Murdoch,
2005), we analyzed the expression of HIF-1α and HIF-1β mRNA in MC38-Ctrl and
MC38-Six1. An increase in mRNA for both HIF-1α and HIF-1 β was observed in
MC38-Six1 (Figure 5.9C). Increased protein levels of HIF-1α was observed in MC38Six1 tumors compared to control tumors (Figure 5.10D). Furthermore, we detected the
expression of cytokines related to the recruitment of macrophages in response to Six1
overexpression in HCT116 and HT29. We observed increased mRNA of VEGF, CCL2,
CCL5, CSF-1 and CSF-2 in HCT116-Six1, and increased CCL2, CCL5, CSF-1 and CSF2 in HT29-Six1 when compared to their corresponding controls (Figure 5.11).
Although the expression of the cytokines did not follow same pattern, all these
results supporting the conclusion that Six1 overexpression in CRC tumor cells recruit
macrophage. Taken together, our data suggest that Six1 increases the expression of
cytokines that elicit macrophage infiltration into the tumor, which results in CRC tumor
growth, progression and metastasis.
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Figure 5.11 mRNA expressions of VEGF, CCL2, CCL5, CSF-1 and CSF-2 were
detected by real time PCR in HCT116-Ctrl and HCT116-Six1 (A), and HT29-Ctrl and
HT29-Six1 (B).

5.3 DISCUSSION
The Six1 homeoprotein plays an important role in the development of numerous
organs. Inappropriate activation of Six1 expression has been found in various human
cancers, and is associated with increased tumor progression and metastasis, and poor
prognosis (Christensen et al., 2008). Recent studies have shown that the overexpression
of Six1 is associated with decreased survival in advanced-stage CRC, which was related
to EMT, growth and invasion (Li et al., 2014; Ono et al., 2012). In addition, we observed
increased expression of Six1 in the intestines from C57BL/6-APCMin/+ mice compared to
that from wild type C57BL/6 mice, and dramatically increased expression of Six1 in
tumors from C57BL/6-APCMin/+ mice, indicating Six1 overexpression may be involved
in early stages of CRC as well. In the present study, we determined that overexpression
of Six1 in the mouse colon cancer cell line MC38 dramatically enhanced CRC tumor
growth and metastasis in vivo. We then found that Six1 increased the population of CSCs
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and stimulated angiogenesis to promote CRC progression. Moreover, we identified that
Six1 overexpression induced macrophage chemotaxis most likely by increasing the
expression of CSF-1, CCL2/5 and VEGF, thereby further facilitating CRC tumor growth
and metastasis.
An important component of the tumor microenvironment is stromal cells.
Stromal cells can be recruited by molecular signals from the cancer cells and cooperate
with the cancer cells to support tumor progression, by enhancing primary tumor growth
as well as enabling metastatic spread (Hanahan and Coussens, 2012). For example, tumor
cells produce VEGF, a potent angiogenic factor, to induce endothelial cell proliferation
and migration and promote angiogenesis. These new blood vessels help satisfy the
oxygen and other metabolic needs of the tumor, provides a potential escape route for
cancer cells, and thereby facilitates tumor progression and metastasis (Woodhouse,
Chuaqui, and Liotta, 1997; Xu et al., 2006). To explore the role of Six1overexpression in
CRC progression, we used an orthotopic CRC mouse model, in which tumor cells grow
in the cecum of immunocompetent mice. We discovered that Six1 overexpression not
only affects tumor cell malignancy by increasing CSC-like characteristics, but also
promotes remodeling of the tumor stroma by stimulating angiogenesis and recruiting
TAM.
Metastasis is the spread of cancer cells from the primary tumor site to distant
organs and is the leading cause of death for CRC patients (Society, 2013; Steeg, 2006).
The liver is one of the most common sites of CRC metastasis (Schima et al., 2005).
Cancer cell metastasis involves the following steps: local invasion, intravasation, travel
through the circulation, arrest and extravasation and proliferation at the distant site
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(Reymond, d'Agua, and Ridley, 2013). To investigate the role of Six1 in CRC metastasis,
we used a splenic injection model to estimate liver metastasis. We chose this model
because spontaneous liver metastasis in the orthotopic CRC model is very rare and not
adequate to assess whether Six1 contributes to metastasis. The splenic injection model
mimics spontaneous liver metastasis by recapitulating early dissemination and later
extravasation and colonization of the liver (Lavilla-Alonso et al., 2011). Using this model,
we demonstrate a dramatic increase in liver metastasis of CRC in Six1-overexpressing
tumor-bearing mice compared to the control mice, suggesting that Six1 facilitates CRC
metastasis.
EMT has been considered a critical step in mediating tumor metastasis
(Christiansen and Rajasekaran, 2006) and a loss of E-cadherin has been shown to lead to
early metastasis (Perl et al., 1998). The correlation between Six1 overexpression and
EMT has been established in breast and colon cancer (Micalizzi et al., 2009; Ono et al.,
2012). In addition, our previous results showed Six1 induced EMT during HPV16mediated transformation (Xu et al., 2014). In this study, we observed a significant
decrease of E-cadherin in SW480 cells overexpressing Six1; but surprisingly, only a
slight decrease was observed in MC38 and HCT116 cells overexpressing Six1. Overall
these observations indicate that EMT may be important for the increase of CRC cell
migration and invasion found associated with Six1 overexpression, but the extent of the
mesenchymal phenotype is different among the different CRC cell lines. Furthermore, we
showed increased expression of VEGF and MMP9 in response to Six1 overexpression,
which promotes tumor angiogenesis and metastasis (Egeblad and Werb, 2002; Hanrahan
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et al., 2003; Lopez-Otin and Matrisian, 2007; Martin and Matrisian, 2007), and may
explain how Six1 promotes CRC progression.
Ample clinical and experimental evidence has demonstrated the promotive role of
TAM on tumorigenesis (Qian and Pollard, 2010). During the early stages of tumor
development macrophages promote an inflammatory environment in the tumor. During
later stages of tumor progression, macrophages stimulate angiogenesis, enhance tumor
cell migration and invasion, and regulate anti-tumor immunity. For example, clinical
studies have shown that overexpression of CSF-1, the major regulator of macrophages, is
associated with poor prognosis in various cancers, including CRC (Mroczko et al., 2007).
Macrophages produce epidermal growth factor (EGF), which activates migration in
tumor cells. Moreover, macrophages accumulate in hypoxic areas of the tumor and
constitutively express HIF-1α, which regulates the transcription of genes associated with
angiogenesis, including VEGF. Tumor cells stimulate the production of MMP9 by
macrophages, which disrupts extra-cellular matrix (ECM), and thus promotes cell
invasion (reviewed in (Qian and Pollard, 2010)). In our study, we discovered that the
overexpression of Six1 in CRC grown as orthotopic tumor induces TAM infiltration by
enhancing the expression of CSF-1, CCL2/5 and VEGF. The recruited TAM reciprocally
secrete molecules that are beneficial for the tumors, such as VEGF and MMP9, and
further promote tumor angiogenesis and metastasis.
Enhanced MAPK signaling is a common event in tumors, and the link between
MAPK signaling and cancer cell survival, angiogenesis and metastasis is well established
(Fang and Richardson, 2005; Mansour et al., 1994). For example, studies based on human
CRC samples indicate a significant correlation between VEGF expression and ERK
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activation (Cassano et al., 2002). The p38 MAPK pathway regulates the expression of
MMP9, which is critical for the migration and invasion of various cancers, including
CRC (Ringshausen et al., 2004; Simon et al., 2001; Wei et al., 2013). The activation of
p38 is essential for the expression of HIF-1α and VEGF, which promotes tumor
angiogenesis (Duyndam et al., 2003; Yoshino et al., 2006). In addition, activation of p38
signaling results in an increase in the CSC population found under hypoxia conditions
and serum depletion (Lin et al., 2012). Similarly, ERK-dependent signaling pathway
regulates MMP9 mediated cell invasion (Lakka et al., 2002). Epidermal growth factor
receptor (EGFR)-mediated ERK activation propagates human prostate CSCs (Rybak,
Ingram, and Tang, 2013). Moreover, we have previously found that Six1overexpression
results in differentiation resistance, promotes EMT and induces features of CSC in
HPV16-immortalized HKc by the activation of MAPK signaling ((Xu et al., 2014) and
our unpublished data). Iwanaga et al. found that Six1 significantly correlates with
phosphorylated ERK in human breast cancers, and Six1 overexpression increases tumor
initiating cells by activation of ERK (Iwanaga et al., 2012). Here, we demonstrate that the
overexpression of Six1 induces the activation of ERK and p38 in both mouse and human
CRC cell lines. Thus, we propose that the MAPK activation may be a common
mechanism leading to tumor progression in Six1-overexpressing tumors and inhibiting
the MAPK pathway could be a potential therapeutic approach for the treatment of these
malignancies.
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